



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C07K 15/28, 3/20, C07H 21/04 C12P 21/08, C12N 15/00, 15/03</b>	<b>A1</b>	(11) International Publication Number: <b>WO 93/11161</b> (43) International Publication Date: <b>10 June 1993 (10.06.93)</b>
(21) International Application Number: <b>PCT/US92/09965</b>		(74) Agents: <b>GOLDSTEIN, Jorge, A. et al.; Sterne, Kessler, Goldstein &amp; Fox, 1225 Connecticut Avenue, N.W., Suite 300, Washington, DC 20036 (US).</b>
(22) International Filing Date: <b>20 November 1992 (20.11.92)</b>		(81) Designated States: <b>AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).</b>
(30) Priority data: <b>07/796,936 25 November 1991 (25.11.91) US</b>		Published <i>With international search report.</i>
(71) Applicant: <b>ENZON, INC. [US/US]; 40 Kingsbridge Road, Piscataway, NJ 08854 (US).</b>		
(72) Inventors: <b>WHITLOW, Marc, D. ; 18727 Cross Country Lane, Gaithersburg, MD 20879 (US). WOOD, James, F. ; 18223 Smoke House Court, Germantown, MD 20874 (US). HARDMAN, Karl ; 1354 Indian Creek Drive, Wynnewood, PA 19096 (US). BIRD, Robert, E. ; 5206 Russett Road, Rockville, MD 20853 (US). FILPULA, David ; 17022 King James Way, Gaithersburg, MD 20877 (US). ROLLENCE, Michele ; 11 Valley Park Court, Damascus, MD 20872 (US).</b>		

**(54) Title: MULTIVALENT ANTIGEN-BINDING PROTEINS****(57) Abstract**

Compositions of, genetic constructions coding for, and methods for producing multivalent antigen-binding proteins are described and claimed. The methods include purification of compositions containing both monomeric and multivalent forms of single polypeptide chain molecules, and production of multivalent proteins from purified monomers. Production of multivalent proteins may occur by a concentration-dependent association of monomeric proteins, or by rearrangement of regions involving dissociation followed by reassociation of different regions. Bivalent proteins, including homobivalent and heterobivalent proteins, are made in the present invention. Genetic sequences coding for bivalent single-chain antigen-binding proteins are disclosed. Uses include all those appropriate for monoclonal and polyclonal antibodies and fragments thereof, including use as a bispecific antigen-binding molecule.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	CA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	CR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MC	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

## Multivalent Antigen-Binding Proteins

This invention was made with Government Support under SBIR Grant 5R44 GM 39662-03 awarded by the National Institutes of Health, National Institute of General Medical Sciences. The Government has certain rights in the invention.

### *Cross-Reference to Related Applications*

This application is a continuation-in-part of U.S. Patent Application Serial Number 07/796,936, filed Nov. 25, 1991, which is a continuation-in-part of U.S. Patent Application Serial No. 07/512,910 filed April 25, 1990, which is a continuation-in-part of Serial No. 07/299,617, filed Jan. 1, 1989, issued as U.S. Patent No. 4,946,778 (Ladner *et al.*), which was a continuation-in-part of Serial No. 092,110, filed Sept. 2, 1987, and Serial No. 902,971, filed Sept. 2, 1986, now abandoned, the contents of all of which are fully incorporated herein by reference.

### *Background of the Invention*

#### *1. Field of the Invention*

The present invention relates generally to the production of antigen-binding molecules. More specifically, the invention relates to multivalent forms of antigen-binding proteins. Compositions of, genetic constructions for, methods of use, and methods for producing these multivalent antigen-binding proteins are disclosed.

## 2. *Description of the Background Art*

Antibodies are proteins generated by the immune system to provide a specific molecule capable of complexing with an invading molecule, termed an antigen. Figure 14 shows the structure of a typical antibody molecule. 5 Natural antibodies have two identical antigen-binding sites, both of which are specific to a particular antigen. The antibody molecule "recognizes" the antigen by complexing its antigen-binding sites with areas of the antigen termed epitopes. The epitopes fit into the conformational architecture of the antigen-binding sites of the antibody, enabling the antibody to bind to the 10 antigen.

The antibody molecule is composed of two identical heavy and two identical light polypeptide chains, held together by interchain disulfide bonds (see Fig. 14). The remainder of this discussion will refer only to one light/heavy pair of chains, as each light/heavy pair is identical. Each 15 individual light and heavy chain folds into regions of approximately 110 amino acids, assuming a conserved three-dimensional conformation. The light chain comprises one variable region (termed  $V_L$ ) and one constant region ( $C_L$ ), while the heavy chain comprises one variable region ( $V_H$ ) and three constant regions ( $C_H1$ ,  $C_H2$  and  $C_H3$ ). Pairs of regions associate to form discrete structures as 20 shown in Figure 14. In particular, the light and heavy chain variable regions,  $V_L$  and  $V_H$ , associate to form an " $F_v$ " area which contains the antigen-binding site.

The variable regions of both heavy and light chains show considerable 25 variability in structure and amino acid composition from one antibody molecule to another, whereas the constant regions show little variability. The term "variable" as used in this specification refers to the diverse nature of the amino acid sequences of the antibody heavy and light chain variable regions. Each antibody recognizes and binds antigen through the binding site defined by the association of the heavy and light chain variable regions into an  $F_v$  area. The light-chain variable region  $V_L$  and the heavy-chain variable region 30  $V_H$  of a particular antibody molecule have specific amino acid sequences that

allow the antigen-binding site to assume a conformation that binds to the antigen epitope recognized by that particular antibody.

Within the variable regions are found regions in which the amino acid sequence is extremely variable from one antibody to another. Three of these so-called "hypervariable" regions or "complementarity-determining regions" (CDR's) are found in each of the light and heavy chains. The three CDR's from a light chain and the three CDR's from a corresponding heavy chain form the antigen-binding site.

Cleavage of the naturally-occurring antibody molecule with the proteolytic enzyme papain generates fragments which retain their antigen-binding site. These fragments, commonly known as Fab's (for Fragment, antigen binding site) are composed of the  $C_L$ ,  $V_L$ ,  $C_H1$  and  $V_H$  regions of the antibody. In the Fab the light chain and the fragment of the heavy chain are covalently linked by a disulfide linkage.

Recent advances in immunobiology, recombinant DNA technology, and computer science have allowed the creation of single polypeptide chain molecules that bind antigen. These single-chain antigen-binding molecules incorporate a linker polypeptide to bridge the individual variable regions,  $V_L$  and  $V_H$ , into a single polypeptide chain. A computer-assisted method for linker design is described more particularly in U.S. Patent No. 4,704,692, issued to Ladner *et al.* in November, 1987, and incorporated herein by reference. A description of the theory and production of single-chain antigen-binding proteins is found in U.S. Patent No. 4,946,778 (Ladner *et al.*), issued August 7, 1990, and incorporated herein by reference. The single-chain antigen-binding proteins produced under the process recited in U.S. Patent 4,946,778 have binding specificity and affinity substantially similar to that of the corresponding Fab fragment.

Bifunctional, or bispecific, antibodies have antigen binding sites of different specificities. Bispecific antibodies have been generated to deliver cells, cytotoxins, or drugs to specific sites. An important use has been to deliver host cytotoxic cells, such as natural killer or cytotoxic T cells, to specific cellular targets. (U.D. Staerz, O. Kanagawa, M.J. Bevan, *Nature*

- 4 -

314:628 (1985); S. Songilvilai, P.J. Lachmann, *Clin. Exp. Immunol.* 79: 315 (1990)). Another important use has been to deliver cytotoxic proteins to specific cellular targets. (V. Raso, T. Griffin, *Cancer Res.* 41:2073 (1981); S. Honda, Y. Ichimori, S. Iwasa, *Cytotechnology* 4:59 (1990)). Another important use has been to deliver anti-cancer non-protein drugs to specific cellular targets (J. Corvalan, W. Smith, V. Gore, *Intl. J. Cancer Suppl.* 2:22 (1988); M. Pimm *et al.*, *British J. of Cancer* 61:508 (1990)). Such bispecific antibodies have been prepared by chemical cross-linking (M. Brennan *et al.*, *Science* 229:81 (1985)), disulfide exchange, or the production of hybrid-hybridomas (quadromas). Quadromas are constructed by fusing hybridomas that secrete two different types of antibodies against two different antigens (Kurokawa, T. *et al.*, *Biotechnology* 7:1163 (1989)).

### *Summary of the Invention*

This invention relates to the discovery that multivalent forms of single-chain antigen-binding proteins have significant utility beyond that of the monovalent single-chain antigen-binding proteins. A multivalent antigen-binding protein has more than one antigen-binding site. Enhanced binding activity, di- and multi-specific binding, and other novel uses of multivalent antigen-binding proteins have been demonstrated or are envisioned here. Accordingly, the invention is directed to multivalent forms of single-chain antigen-binding proteins, compositions of multivalent and single-chain antigen-binding proteins, methods of making and purifying multivalent forms of single-chain antigen-binding proteins, and uses for multivalent forms of single-chain antigen-binding proteins. The invention provides a multivalent antigen-binding protein comprising two or more single-chain protein molecules, each single-chain molecule comprising a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and a peptide linker linking the first and second polypeptides into a single-chain protein.

Also provided is a composition comprising a multivalent antigen-binding protein substantially free of single-chain molecules.

Also provided is an aqueous composition comprising an excess of multivalent antigen-binding protein over single-chain molecules.

5 A method of producing a multivalent antigen-binding protein is provided, comprising the steps of producing a composition comprising multivalent antigen-binding protein and single-chain molecules, each single-chain molecule comprising a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and a peptide linker linking the first and second polypeptides into a single-chain molecule; separating the multivalent protein 10 from the single-chain molecules; and recovering the multivalent protein.

15 Also provided is a method of producing multivalent antigen-binding protein, comprising the steps of producing a composition comprising single-chain molecules as previously defined; dissociating the single-chain molecules; reassociating the single-chain molecules; separating the resulting multivalent antigen-binding proteins from the single-chain molecules; and recovering the multivalent proteins.

20 Also provided is another method of producing a multivalent antigen-binding protein, comprising the step of chemically cross-linking at least two single-chain antigen-binding molecules.

25 Also provided is another method of producing a multivalent antigen-binding protein, comprising the steps of producing a composition comprising single-chain molecules as previously defined; concentrating said single-chain molecules; separating said multivalent protein from said single-chain molecules; and finally recovering said multivalent protein.

30 Also provided is another method of producing a multivalent antigen-binding protein comprising two or more single-chain molecules, each single-chain molecule as previously defined, said method comprising: providing a genetic sequence coding for said single-chain molecule; transforming a host

cell or cells with said sequence; expressing said sequence in said host or hosts; and recovering said multivalent protein.

Another aspect of the invention includes a method of detecting an antigen in or suspected of being in a sample, which comprises contacting said sample with the multivalent antigen-binding protein of claim 1 and detecting whether said multivalent antigen-binding protein has bound to said antigen.

Another aspect of the invention includes a method of imaging the internal structure of an animal, comprising administering to said animal an effective amount of a labeled form of the multivalent antigen-binding protein of claim 1 and measuring detectable radiation associated with said animal.

Another aspect of the invention includes a composition comprising an association of a multivalent antigen-binding protein with a therapeutically or diagnostically effective agent.

Another aspect of this invention is a single-chain protein comprising: a first polypeptide comprising the binding portion of the variable region of an antibody light chain; a second polypeptide comprising the binding portion of the variable region of an antibody light chain; a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

Another aspect of the present invention includes the genetic constructions encoding the combinations of regions  $V_L$ - $V_L$  and  $V_H$ - $V_H$  for single-chain molecules, and encoding multivalent antigen-binding proteins.

Another part of this invention is a multivalent single-chain antigen-binding protein comprising: a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; a peptide linker linking said first and second polypeptides (a) and (b) into said multivalent protein; a third polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; a fourth polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; a peptide linker linking said third and fourth polypeptides (d) and (e) into said multivalent protein; and a peptide linker linking said second and third polypeptides (b) and (d) into said

multivalent protein. Also included are genetic constructions coding for this multivalent single-chain antigen-binding protein.

Also included are replicable cloning or expression vehicles including plasmids, hosts transformed with the aforementioned genetic sequences, and methods of producing multivalent proteins with the sequences, transformed hosts, and expression vehicles.

Methods of use are provided, such as a method of using the multivalent antigen-binding protein to diagnose a medical condition; a method of using the multivalent protein as a carrier to image the specific bodily organs of an animal; a therapeutic method of using the multivalent protein to treat a medical condition; and an immunotherapeutic method of conjugating a multivalent protein with a therapeutically or diagnostically effective agent. Also included are labelled multivalent proteins, improved immunoassays using them, and improved immunoaffinity purifications.

An advantage of using multivalent antigen-binding proteins instead of single-chain antigen-binding molecules or Fab fragments lies in the enhanced binding ability of the multivalent form. Enhanced binding occurs because the multivalent form has more binding sites per molecule. Another advantage of the present invention is the ability to use multivalent antigen-binding proteins as multi-specific binding molecules.

An advantage of using multivalent antigen-binding proteins instead of whole antibodies, is the enhanced clearing of the multivalent antigen-binding proteins from the serum due to their smaller size as compared to whole antibodies which may afford lower background in imaging applications.

Multivalent antigen-binding proteins may penetrate solid tumors better than monoclonals, resulting in better tumor-fighting ability. Also, because they are smaller and lack the Fc component of intact antibodies, the multivalent antigen-binding proteins of the present invention may be less immunogenic than whole antibodies. The Fc component of whole antibodies also contains binding sites for liver, spleen and certain other cells and its absence should thus reduce accumulation in non-target tissues.

Another advantage of multivalent antigen-binding proteins is the ease with which they may be produced and engineered, as compared to the myeloma-fusing technique pioneered by Kohler and Milstein that is used to produce whole antibodies.

5

### *Brief Description of the Drawings.*

The present invention as defined in the claims can be better understood with reference to the text and to the following drawings:

10

FIG. 1A is a schematic two-dimensional representation of two identical single-chain antigen-binding protein molecules, each comprising a variable light chain region ( $V_L$ ), a variable heavy chain region ( $V_H$ ), and a polypeptide linker joining the two regions. The single-chain antigen-binding protein molecules are shown binding antigen in their antigen-binding sites.

15

FIG. 1B depicts a hypothetical homodivalent antigen-binding protein formed by association of the polypeptide linkers of two monovalent single-chain antigen-binding proteins from Fig. 1A (the Association model). The divalent antigen-binding protein is formed by the concentration-driven association of two identical single-chain antigen-binding protein molecules.

20

FIG. 1C depicts the hypothetical divalent protein of FIG. 1B with bound antigen molecules occupying both antigen-binding sites.

FIG. 2A depicts the hypothetical homodivalent protein of Figure 1B.

FIG. 2B depicts three single-chain antigen-binding protein molecules associated in a hypothetical trimer.

FIG. 2C depicts a hypothetical tetramer of four single-chain antigen-binding protein molecules.

25

FIG. 3A depicts two separate and distinct monovalent single-chain antigen-binding proteins, Anti-A single-chain antigen-binding protein and Anti-B single-chain antigen-binding protein, with different antigen specificities, each individually binding either Antigen A or Antigen B.

FIG. 3B depicts a hypothetical bispecific heterodivalent antigen-binding protein formed from the single-chain antigen-binding proteins of Fig. 3A according to the Association model.

5 FIG. 3C depicts the hypothetical heterodivalent antigen-binding protein of FIG. 3B binding bispecifically, i.e., binding the two different antigens, A and B.

10 FIG. 4A depicts two identical single-chain antigen-binding protein molecules, each having a variable light chain region ( $V_L$ ), a variable heavy chain region ( $V_H$ ), and a polypeptide linker joining the two regions. The single-chain antigen-binding protein molecules are shown binding identical antigen molecules in their antigen-binding sites.

15 FIG. 4B depicts a hypothetical homodivalent protein formed by the rearrangement of the  $V_L$  and  $V_H$  regions shown in FIG. 4A (the Rearrangement model). Also shown is bound antigen.

20 FIG. 5A depicts two single-chain protein molecules, the first having an anti-B  $V_L$  and an anti-A  $V_H$ , and the second having an anti-A  $V_L$  and an anti-B  $V_H$ . The figure shows the non-complementary nature of the  $V_L$  and  $V_H$  regions in each single-chain protein molecule.

25 FIG. 5B shows a hypothetical bispecific heterodivalent antigen-binding protein formed by rearrangement of the two single-chain proteins of Figure 5A.

30 FIG. 5C depicts the hypothetical heterodivalent antigen-binding protein of FIG. 5B with different antigens A and B occupying their respective antigen-binding sites.

FIG. 6A is a schematic depiction of a hypothetical trivalent antigen-binding protein according to the Rearrangement model.

FIG. 6B is a schematic depiction of a hypothetical tetravalent antigen-binding protein according to the Rearrangement model.

35 FIG. 7 is a chromatogram depicting the separation of CC49/212 antigen-binding protein monomer from dimer on a cation exchange high performance liquid chromatographic column. The column is a PolyCAT A

- 10 -

aspartic acid column (Poly WC, Columbia, MD). Monomer is shown as Peak 1, eluting at 27.32 min., and dimer is shown as Peak 2, eluting at 55.52 min.

5 FIG. 8 is a chromatogram of the purified monomer from Fig. 7. Monomer elutes at 21.94 min., preceded by dimer (20.135 min.) and trimer (18.640 min.). Gel filtration column, Protein-Pak 300SW (Waters Associates, Milford, MA).

FIG. 9 is a similar chromatogram of purified dimer (20.14 min.) from Fig. 7, run on the gel filtration HPLC column of Fig. 8.

10 FIG. 10A is an amino acid (SEQ ID NO. 11) and nucleotide (SEQ ID NO. 10) sequence of the single-chain protein comprising the 4-4-20 V<sub>L</sub> region connected through the 212 linker polypeptide to the CC49 V<sub>H</sub> region.

15 FIG. 10B is an amino acid (SEQ ID NO. 13) and nucleotide (SEQ ID NO. 12) sequence of the single-chain protein comprising the CC49 V<sub>L</sub> region connected through the 212 linker polypeptide to the 4-4-20 V<sub>H</sub> region.

FIG. 11 is a chromatogram depicting the separation of the monomer (27.83 min.) and dimer (50.47 min.) forms of the CC49/212 antigen-binding protein by cation exchange, on a PolyCAT A cation exchange column (Poly LC, Columbia, MD).

20 Fig. 12 shows the separation of monomer (17.65 min.), dimer (15.79 min.), trimer (14.19 min.), and higher oligomers (shoulder at about 13.09 min.) of the B6.2/212 antigen-binding protein. This separation depicts the results of a 24-hour treatment of a 1.0 mg/ml B6.2/212 single-chain antigen-binding protein sample. A TSK G2000SW gel filtration HPLC column was used, Toyo Soda, Tokyo, Japan.

25 Fig. 13 shows the results of a 24-hour treatment of a 4.0 mg/ml CC49/212 antigen-binding protein sample, generating monomer, dimer, and trimer at 16.91, 14.9, and 13.42 min., respectively. The same TSK gel filtration column was used as in Fig. 12.

30 Fig. 14 shows a schematic view of the four-chain structure of a human IgG molecule.

Fig. 15A is an amino acid (SEQ ID NO. 15) and nucleotide (SEQ ID NO. 14) sequence of the 4-4-20/212 single-chain antigen-binding protein with a single cysteine hinge.

Fig. 15B is an amino acid (SEQ ID NO. 17) and nucleotide (SEQ. ID NO. 16) sequence of the 4-4-20/212 single-chain antigen-binding protein with the two-cysteine hinge.

Fig. 16 shows the amino acid (SEQ ID NO. 19) and nucleotide (SEQ ID NO. 18) sequence of a divalent CC49/212 single-chain antigen-binding protein.

Fig. 17 shows the expression of the divalent CC49/212 single-chain antigen-binding protein of Fig. 16 at 42°C, on an SDS-PAGE gel containing total *E. coli* protein. Lane 1 contains the molecular weight standards. Lane 2 is the uninduced *E. coli* production strain grown at 30°C. Lane 3 is divalent CC49/212 single-chain antigen-binding protein induced by growth at 42°C. The arrow shows the band of expressed divalent CC49/212 single-chain antigen-binding protein.

Fig. 18 is a graphical representation of four competition radioimmunoassays (RIA) in which unlabeled CC49 IgG (open circles) CC49/212 single-chain antigen-binding protein (closed circles) and CC49/212 divalent antigen-binding protein (closed squares) and anti-fluorescein 4-4-20/212 single-chain antigen-binding protein (open squares) competed against a CC49 IgG radiolabeled with <sup>125</sup>I for binding to the TAG-72 antigen on a human breast carcinoma extract.

Figure 19A is an amino acid (SEQ ID NO. 21) and nucleotide (SEQ ID NO. 20) sequence of the single-chain polypeptide comprising the 4-4-20 V<sub>L</sub> region connected through the 217 linker polypeptide to the CC49 V<sub>H</sub> region.

Figure 19B is an amino acid (SEQ ID NO. 23) and nucleotide (SEQ ID NO. 22) sequence of the single-chain polypeptide comprising the CC49 V<sub>L</sub> region connected through the 217 linker polypeptide to the 4-4-20 V<sub>H</sub> region.

Figure 20 is a chromatogram depicting the purification of CC49/4-4-20 heterodimer Fv on a cation exchange high performance liquid chromatographic column. The column is a PolyCAT A aspartic acid column (Poly LC,

- 12 -

Columbia, MD). The heterodimer Fv is shown as peak 5, eluting at 30.10 min.

5 Figure 21 is a coomassie-blue stained 4-20% SDS-PAGE gel showing the proteins separated in Figure 20. Lane 1 contains the molecular weight standards. Lane 3 contains the starting material before separation. Lanes 4-8 contain fractions 2, 3, 5, 6 and 7 respectively. Lane 9 contains purified CC49/212.

10 Figure 22A is a chromatogram used to determine the molecular size of fraction 2 from Figure 20. A TSK G3000SW gel filtration HPLC column was used (Toyo Soda, Tokyo, Japan).

15 Figure 22B is a chromatogram used to determine the molecular size of fraction 5 from Figure 20. A TSK G3000SW gel filtration HPLC column was used (Toyo Soda, Tokyo, Japan).

Figure 22C is a chromatogram used to determine the molecular size of fraction 6 from Figure 20. A TSK G30005W gel filtration HPLC column was used (Toyo Soda, Tokyo, Japan).

Figure 23 shows a Scatchard analysis of the fluorescein binding affinity of the CC49 4-4-20 heterodimer Fv (fraction 5 in Figure 20).

20 Figure 24 is a graphical representation of three competition enzyme-linked immunosorbent assays (ELISA) in which unlabeled CC49 4-4-20 Fv (closed squares) CC49/212 single-chain Fv (open squares) and MOPC-21 IgG (+) competed against a biotin-labeled CC49 IgG for binding to the TAG-72 antigen on a human breast carcinoma extract. MOPC-21 is a control antibody that does not bind to TAG-72 antigen.

25 Figure 25 shows a coomassie-blue stained non-reducing 4-20% SDS-PAGE gel. Lanes 1 and 9 contain the molecular weight standards. Lane 3 contains the 4-4-20/212 CPPC single-chain antigen-binding protein after purification. Lane 4, 5 and 6 contain the 4-4-20/212 CPPC single-chain antigen-binding protein after treatment with DTT and air oxidation. Lane 7 contains 4-4-20/212 single-chain antigen-binding protein.

30 Figure 26 shows a coomassie-blue stained reducing 4-20% SDS-PAGE gel (samples were treated with  $\beta$ -mercaptoethanol prior to being loaded on the

gel). Lanes 1 and 8 contain the molecular weight standards. Lane 3 contains the 4-4-20/212 CPPC single-chain antigen-binding protein after treatment with *bis*-maleimidehexane. Lane 5 contains peak 1 of *bis*-maleimidehexane treated 4-4-20/212 CPCC single-chain antigen-binding protein. Lane 6 contains peak 3 of *bis*-maleimidehexane treated 4-4-20/212 CPPC single-chain antigen-binding protein.

### *Detailed Description of the Preferred Embodiments*

This invention relates to the discovery that multivalent forms of single-chain antigen-binding proteins have significant utility beyond that of the monovalent single-chain antigen-binding proteins. A multivalent antigen-binding protein has more than one antigen-binding site. For the purposes of this application, "valent" refers to the numerosity of antigen binding sites. Thus, a bivalent protein refers to a protein with two binding sites. Enhanced binding activity, bi- and multi-specific binding, and other novel uses of multivalent antigen-binding proteins have been demonstrated or are envisioned here. Accordingly, the invention is directed to multivalent forms of single-chain antigen-binding proteins, compositions of multivalent and single-chain antigen-binding proteins, methods of making and purifying multivalent forms of single-chain antigen-binding proteins, and new and improved uses for multivalent forms of single-chain antigen-binding proteins. The invention provides a multivalent antigen-binding protein comprising two or more single-chain protein molecules, each single-chain molecule comprising a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and a peptide linker linking the first and second polypeptides into a single-chain protein.

The term "multivalent" means any assemblage, covalently or non-covalently joined, of two or more single-chain proteins, the assemblage having more than one antigen-binding site. The single-chain proteins composing the

assemblage may have antigen-binding activity, or they may lack antigen-binding activity individually but be capable of assembly into active multivalent antigen-binding proteins. The term "multivalent" encompasses bivalent, trivalent, tetravalent, etc. It is envisioned that multivalent forms above bivalent may be useful for certain applications.

A preferred form of the multivalent antigen-binding protein comprises bivalent proteins, including heterobivalent and homobivalent forms. The term "bivalent" means an assemblage of single-chain proteins associated with each other to form two antigen-binding sites. The term "heterobivalent" indicates multivalent antigen-binding proteins that are bispecific molecules capable of binding to two different antigenic determinants. Therefore, heterobivalent proteins have two antigen-binding sites that have different binding specificities. The term "homobivalent" indicates that the two binding sites are for the same antigenic determinant.

The terms "single-chain molecule" or "single-chain protein" are used interchangeably here. They are structurally defined as comprising the binding portion of a first polypeptide from the variable region of an antibody, associated with the binding portion of a second polypeptide from the variable region of an antibody, the two polypeptides being joined by a peptide linker linking the first and second polypeptides into a single polypeptide chain. The single polypeptide chain thus comprises a pair of variable regions connected by a polypeptide linker. The regions may associate to form a functional antigen-binding site, as in the case wherein the regions comprise a light-chain and a heavy-chain variable region pair with appropriately paired complementarity determining regions (CDRs). In this case, the single-chain protein is referred to as a "single-chain antigen-binding protein" or "single-chain antigen-binding molecule."

Alternatively, the variable regions may have unnaturally paired CDRs or may both be derived from the same kind of antibody chain, either heavy or light, in which case the resulting single-chain molecule may not display a functional antigen-binding site. The single-chain antigen-binding protein

molecule is more fully described in U.S. Patent No. 4,946,778 (Ladner *et al.*), and incorporated herein by reference.

Without being bound by any particular theory, the inventors speculate on several models which can equally explain the phenomenon of multivalence. The inventors' models are presented herein for the purpose of illustration only, and are not to be construed as limitations upon the scope of the invention. The invention is useful and operable regardless of the precise mechanism of multivalence.

Figure 1 depicts the first hypothetical model for the creation of a multivalent protein, the "Association" model. Fig. 1A shows two monovalent single-chain antigen-binding proteins, each composed of a  $V_L$ , a  $V_H$ , and a linker polypeptide covalently bridging the two. Each monovalent single-chain antigen-binding protein is depicted having an identical antigen-binding site containing antigen. Figure 1B shows the simple association of the two single-chain antigen-binding proteins to create the bivalent form of the multivalent protein. It is hypothesized that simple hydrophobic forces between the monovalent proteins are responsible for their association in this manner. The origin of the multivalent proteins may be traceable to their concentration dependence. The monovalent units retain their original association between the  $V_H$  and  $V_L$  regions. Figure 1C shows the newly-formed homobivalent protein binding two identical antigen molecules simultaneously. Homobivalent antigen-binding proteins are necessarily monospecific for antigen.

Homovalent proteins are depicted in Figs. 2A through 2C formed according to the Association model. Fig. 1A depicts a homobivalent protein, Fig. 2B a trivalent protein, and Fig. 2C a tetravalent protein. Of course, the limitations of two-dimensional images of three-dimensional objects must be taken into account. Thus, the actual spatial arrangement of multivalent proteins can be expected to vary somewhat from these figures.

A heterobivalent antigen-binding protein has two different binding sites, the sites having different binding specificities. Figures 3A through C depict the Association model pathway to the creation of a heterobivalent protein. Figure 3A shows two monovalent single-chain antigen-binding proteins, Anti-

A single-chain antigen-binding protein and Anti-B single-chain antigen-binding protein, with antigen types A and B occupying the respective binding sites. Figure 3B depicts the heterobivalent protein formed by the simple association of the original monovalent proteins. Figure 3C shows the heterobivalent protein having bound antigens A and B into the antigen-binding sites. Figure 3C therefore shows the heterobivalent protein binding in a bispecific manner.

An alternative model for the formation of multivalent antigen-binding proteins is shown in Figures 4 through 6. This "Rearrangement" model hypothesizes the dissociation of the variable region interface by contact with dissociating agents such as guanidine hydrochloride, urea, or alcohols such as ethanol, either alone or in combination. Combinations and relevant concentration ranges of dissociating agents are recited in the discussion concerning dissociating agents, and in Example 2. Subsequent re-association of dissociated regions allows variable region recombination differing from the starting single-chain proteins, as depicted in Fig. 4B. The homobivalent antigen-binding protein of Figure 4B is formed from the parent single-chain antigen-binding proteins shown in Figure 4A, the recombined bivalent protein having  $V_L$  and  $V_H$  from the parent monovalent single-chain proteins. The homobivalent protein of Figure 4B is a fully functional monospecific bivalent protein, shown actively binding two antigen molecules.

Figures 5A-5C show the formation of heterobivalent antigen-binding proteins via the Rearrangement model. Figure 5A shows a pair of single-chain proteins, each having a  $V_L$  with complementarity determining regions (CDRs) that do not match those of the associated  $V_H$ . These single-chain proteins have reduced or no ability to bind antigen because of the mixed nature of their antigen-binding sites, and thus are made specifically to be assembled into multivalent proteins through this route. Figure 5B shows the heterobivalent antigen-binding protein formed whereby the  $V_H$  and  $V_L$  regions of the parent proteins are shared between the separate halves of the heterobivalent protein. Figure 5C shows the binding of two different antigen molecules to the resultant functional bispecific heterobivalent protein. The Rearrangement model also explains the generation of multivalent proteins of

a higher order than bivalent, as it can be appreciated that more than a pair of single-chain proteins can be reassembled in this manner. These are depicted in Figures 6A and 6B.

One of the major utilities of the multivalent antigen-binding protein is in the heterobivalent form, in which one specificity is for one type of hapten or antigen, and the second specificity is for a second type of hapten or antigen. A multivalent molecule having two distinct binding specificities has many potential uses. For instance, one antigen binding site may be specific for a cell-surface epitope of a target cell, such as a tumor cell or other undesirable cell. The other antigen-binding site may be specific for a cell-surface epitope of an effector cell, such as the CD3 protein of a cytotoxic T-cell. In this way, the heterobivalent antigen-binding protein may guide a cytotoxic cell to a particular class of cells that are to be preferentially attacked.

Other uses of heterobivalent antigen-binding proteins are the specific targeting and destruction of blood clots by a bispecific molecule with specificity for tissue plasminogen activator (tPA) and fibrin; the specific targeting of pro-drug activating enzymes to tumor cells by a bispecific molecule with specificity for tumor cells and enzyme; and specific targeting of cytotoxic proteins to tumor cells by a bispecific molecule with specificity for tumor cells and a cytotoxic protein. This list is illustrative only, and any use for which a multivalent specificity is appropriate comes within the scope of this invention.

The invention also extends to uses for the multivalent antigen-binding proteins in purification and biosensors. Affinity purification is made possible by affixing the multivalent antigen-binding protein to a support, with the antigen-binding sites exposed to and in contact with the ligand molecule to be separated, and thus purified. Biosensors generate a detectable signal upon binding of a specific antigen to an antigen-binding molecule, with subsequent processing of the signal. Multivalent antigen-binding proteins, when used as the antigen-binding molecule in biosensors, may change conformation upon binding, thus generating a signal that may be detected.

Essentially all of the uses for which monoclonal or polyclonal antibodies, or fragments thereof, have been envisioned by the prior art, can be addressed by the multivalent proteins of the present invention. These uses include detectably-labelled forms of the multivalent protein. Types of labels are well-known to those of ordinary skill in the art. They include radiolabelling, chemiluminescent labeling, fluorochromic labelling, and chromophoric labeling. Other uses include imaging the internal structure of an animal (including a human) by administering an effective amount of a labelled form of the multivalent protein and measuring detectable radiation associated with the animal. They also include improved immunoassays, including sandwich immunoassay, competitive immunoassay, and other immunoassays wherein the labelled antibody can be replaced by the multivalent antigen-binding protein of this invention.

A first preferred method of producing multivalent antigen-binding proteins involves separating the multivalent proteins from a production composition that comprises both multivalent and single-chain proteins, as represented in Example 1. The method comprises producing a composition of multivalent and single-chain proteins, separating the multivalent proteins from the single-chain proteins, and recovering the multivalent proteins.

A second preferred method of producing multivalent antigen-binding proteins comprises the steps of producing single-chain protein molecules, dissociating said single-chain molecules, reassociating the single-chain molecules such that a significant fraction of the resulting composition includes multivalent forms of the single-chain antigen-binding proteins, separating multivalent antigen-binding proteins from single-chain molecules, and recovering the multivalent proteins. This process is illustrated with more detail in Example 2. For the purposes of this method, the term "producing a composition comprising single-chain molecules" may indicate the actual production of these molecules. The term may also include procuring them from whatever commercial or institutional source makes them available. Use of the term "producing single-chain proteins" means production of single-chain proteins by any process, but preferably according to the process set forth in

U.S. Patent No. 4,946,778 (Ladner *et al.*). Briefly, that patent pertains to a single polypeptide chain antigen-binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the aggregate light and heavy chain variable regions of an antibody, to genetic sequences coding therefore, and to recombinant DNA methods of producing such molecules, and uses for such molecules. The single-chain protein produced by the Ladner *et al.* methodology comprises two regions linked by a linker polypeptide. The two regions are termed the  $V_H$  and  $V_L$  regions, each region comprising one half of a functional antigen-binding site.

The term "dissociating said single-chain molecules" means to cause the physical separation of the two variable regions of the single-chain protein without causing denaturation of the variable regions.

"Dissociating agents" are defined herein to include all agents capable of dissociating the variable regions, as defined above. In the context of this invention, the term includes the well-known agents alcohol (including ethanol), guanidine hydrochloride (GuHCl), and urea. Others will be apparent to those of ordinary skill in the art, including detergents and similar agents capable of interrupting the interactions that maintain protein conformation. In the preferred embodiment, a combination of GuHCl and ethanol (EtOH) is used as the dissociating agent. A preferred range for ethanol and GuHCl is from 0 to 50% EtOH, vol/vol, 0 to 2.0 moles per liter (M) GuHCl. A more preferred range is from 10-30% EtOH and 0.5-1.0 M GuHCl, and a most preferred range is 20% EtOH, 0.5 M GuHCl. A preferred dissociation buffer contains 0.5 M guanidine hydrochloride, 20% ethanol, 0.05 M TRIS, and 0.01 M  $CaCl_2$ , pH 8.0.

Use of the term "re-associating said single-chain molecules" is meant to describe the reassociation of the variable regions by contacting them with a buffer solution that allows reassociation. Such a buffer is preferably used in the present invention and is characterized as being composed of 0.04 M MOPS, 0.10 M calcium acetate, pH 7.5. Other buffers allowing the reassociation of the  $V_L$  and  $V_H$  regions are well within the expertise of one of ordinary skill in the art.

The separation of the multivalent protein from the single-chain molecules occurs by use of standard techniques known in the art, particularly including cation exchange or gel filtration chromatography.

Cation exchange chromatography is the general liquid chromatographic technique of ion-exchange chromatography utilizing anion columns well-known to those of ordinary skill in the art. In this invention, the cations exchanged are the single-chain and multivalent protein molecules. Since multivalent proteins will have some multiple of the net charge of the single-chain molecule, the multivalent proteins are retained more strongly and are thus separated from the single-chain molecules. The preferred cationic exchanger of the present invention is a polyaspartic acid column, as shown in Figure 7. Figure 7 depicts the separation of single-chain protein (Peak 1, 27.32 min.) from bivalent protein (Peak 2, 55.54 min.) Those of ordinary skill in the art will realize that the invention is not limited to any particular type of chromatography column, so long as it is capable of separating the two forms of protein molecules.

Gel filtration chromatography is the use of a gel-like material to separate proteins on the basis of their molecular weight. A "gel" is a matrix of water and a polymer, such as agarose or polymerized acrylamide. The present invention encompasses the use of gel filtration HPLC (high performance liquid chromatography), as will be appreciated by one of ordinary skill in the art. Figure 8 is a chromatogram depicting the use of a Waters Associates' Protein-Pak 300 SW gel filtration column to separate monovalent single-chain protein from multivalent protein, including the monomer (21.940 min.), bivalent protein (20.135 min.), and trivalent protein (18.640 min.).

Recovering the multivalent antigen-binding proteins is accomplished by standard collection procedures well known in the chemical and biochemical arts. In the context of the present invention recovering the multivalent protein preferably comprises collection of eluate fractions containing the peak of interest from either the cation exchange column, or the gel filtration HPLC column. Manual and automated fraction collection are well-known to one of

ordinary skill in the art. Subsequent processing may involve lyophilization of the eluate to produce a stable solid, or further purification.

A third preferred method of producing multivalent antigen-binding proteins is to start with purified single-chain proteins at a lower concentration, and then increase the concentration until some significant fraction of multivalent proteins is formed. The multivalent proteins are then separated and recovered. The concentrations conducive to formation of multivalent proteins in this manner are from about 0.5 milligram per milliliter (mg/ml) to the concentration at which precipitates begin to form.

The use of the term "substantially free" when used to describe a composition of multivalent and single-chain antigen-binding protein molecules means the lack of a significant peak corresponding to the single-chain molecule, when the composition is analyzed by cation exchange chromatography, as disclosed in Example 1 or by gel filtration chromatography as disclosed in Example 2.

By use of the term "aqueous composition" is meant any composition of single-chain molecules and multivalent proteins including a portion of water. In the same context, the phrase "an excess of multivalent antigen-binding protein over single-chain molecules" indicates that the composition comprises more than 50% of multivalent antigen-binding protein.

The use of the term "cross-linking" refers to chemical means by which one can produce multivalent antigen-binding proteins from monovalent single-chain protein molecules. For example, the incorporation of a cross-linkable sulphydryl chemical group as a cysteine residue in the single-chain proteins allows cross-linking by mild reduction of the sulphydryl group. Both monospecific and multispecific multivalent proteins can be produced from single-chain proteins by cross-linking the free cysteine groups from two or more single-chain proteins, causing a covalent chemical linkage to form between the individual proteins. Free cysteines have been engineered into the C-terminal portion of the 4-4-20/212 single-chain antigen-binding protein, as discussed in Example 5 and Example 8. These free cysteines may then be cross-linked to form multivalent antigen-binding proteins.

5                   The invention also comprises single-chain proteins, comprising: (a) a first polypeptide comprising the binding portion of the variable region of an antibody light chain; (b) a second polypeptide comprising the binding portion of the variable region of an antibody light chain; and (c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein. A similar single-chain protein comprising the heavy chain variable regions is also a part of this invention. Genetic sequences encoding these molecules are also included in the scope of this invention. Since these proteins are comprised of two similar variable regions, they do not necessarily have 10 any antigen-binding capability.

15                  The invention also includes a DNA sequence encoding a bispecific bivalent antigen-binding protein. Example 4 and Example 7 discusses in detail the sequences that appear in Figs. 10A and 10B that allow one of ordinary skill to construct a heterobivalent antigen-binding molecule. Figure 10A is an amino acid and nucleotide sequence listing of the single-chain protein comprising the 4-4-20  $V_L$  region connected through the 212 linker polypeptide to the CC49  $V_H$  region. Figure 10B is a similar listing of the single-chain protein comprising the CC49  $V_L$  region connected through the 212 linker polypeptide to the 4-4-20  $V_H$  region. Subjecting a composition including these 20 single-chain molecules to dissociating and subsequent re-associating conditions results in the production of a bivalent protein with two different binding specificities.

25                  Synthesis of DNA sequences is well known in the art, and possible through at least two routes. First, it is well-known that DNA sequences may be synthesized through the use of automated DNA synthesizers *de novo*, once the primary sequence information is known. Alternatively, it is possible to obtain a DNA sequence coding for a multivalent single-chain antigen-binding protein by removing the stop codons from the end of a gene encoding a single-chain antigen-binding protein, and then inserting a linker and a gene encoding 30 a second single-chain antigen-binding protein. Example 6 demonstrates the construction of a DNA sequence coding for a bivalent single-chain antigen-binding protein. Other methods of genetically constructing multivalent single-

chain antigen-binding proteins come within the spirit and scope of the present invention.

Having now generally described this invention the same will better be understood by reference to certain specific examples which are included for purposes of illustration and are not intended to limit it unless otherwise specified.

### *Example 1*

#### *Production of Multivalent Antigen-Binding Proteins During Purification*

In the production of multivalent antigen-binding proteins, the same recombinant *E. coli* production system that was used for prior single-chain antigen-binding protein production was used. See Bird, *et al.*, *Science* 242:423 (1988). This production system produced between 2 and 20% of the total *E. coli* protein as antigen-binding protein. For protein recovery, the frozen cell paste from three 10-liter fermentations (600-900 g) was thawed overnight at 4°C and gently resuspended at 4°C in 50 mM Tris-HCl, 1.0 mM EDTA, 100 mM KCl, 0.1 mM PMSF, pH 8.0 (lysis buffer), using 10 liters of lysis buffer for every kilogram of wet cell paste. When thoroughly resuspended, the chilled mixture was passed three times through a Manton-Gaulin cell homogenizer to totally lyse the cells. Because the cell homogenizer raised the temperature of the cell lysate to 25 ± 5°C, the cell lysate was cooled to 5 ± 2°C with a Lauda/Brinkman chilling coil after each pass. Complete lysis was verified by visual inspection under a microscope.

The cell lysate was centrifuged at 24,300g for 30 min. at 6°C using a Sorvall RC-5B centrifuge. The pellet containing the insoluble antigen-binding protein was retained, and the supernatant was discarded. The pellet was washed by gently scraping it from the centrifuge bottles and resuspending it in 5 liters of lysis buffer/kg of wet cell paste. The resulting 3.0- to 4.5-liter suspension was again centrifuged at 24,300g for 30 min at 6°C, and the

supernatant was discarded. This washing of the pellet removes soluble *E. coli* proteins and can be repeated as many as five times. At any time during this washing procedure the material can be stored as a frozen pellet at -20°C. A substantial time saving in the washing steps can be accomplished by utilizing a Pellicon tangential flow apparatus equipped with 0.22- $\mu$ m microporous filters, in place of centrifugation.

The washed pellet was solubilized at 4°C in freshly prepared 6 M guanidine hydrochloride, 50 mM Tris-HCl, 10 mM CaCl<sub>2</sub>, 50 mM KCl, pH 8.0 (dissociating buffer), using 9 ml/g of pellet. If necessary, a few quick pulses from a Heat Systems Ultrasonics tissue homogenizer can be used to complete the solubilization. The resulting suspension was centrifuged at 24,300g for 45 min at 6°C and the pellet was discarded. The optical density of the supernatant was determined at 280 nm and if the OD<sub>280</sub> was above 30, additional dissociating buffer was added to obtain an OD<sub>280</sub> of approximately 25.

The supernatant was slowly diluted into cold (4-7°C) refolding buffer (50 mM Tris-HCl, 10 mM CaCl<sub>2</sub>, 50 mM KCl, pH 8.0) until a 1:10 dilution was reached (final volume 10-20 liters). Re-folding occurs over approximately eighteen hours under these conditions. The best results are obtained when the GuHCl extract is slowly added to the refolding buffer over a 2-h period, with gentle mixing. The solution was left undisturbed for at least a 20-h period, and 95% ethanol was added to this solution such that the final ethanol concentration was approximately 20%. This solution was left undisturbed until the flocculated material settled to the bottom, usually not less than sixty minutes. The solution was filtered through a 0.2 um Millipore Millipak 200. This filtration step may be optionally preceded by a centrifugation step. The filtrate was concentrated to 1 to 2 liters using an Amicon spiral cartridge with a 10,000 MWCO cartridge, again at 4°C.

The concentrated crude antigen-binding protein sample was dialyzed against Buffer A (60 mM MOPS, 0.5 mM Ca acetate, pH 6.0-6.4) until the conductivity was lowered to that of Buffer A. The sample was then loaded on a 21.5 x 250-mm polyaspartic acid PolyCAT A column, manufactured by Poly

LC of Columbia, Maryland. If more than 60 mg of protein is loaded on this column, the resolution begins to deteriorate; thus, the concentrated crude sample often must be divided into several PolyCAT A runs. Most antigen-binding proteins have an extinction coefficient of about  $2.0 \text{ ml mg}^{-1} \text{ cm}^{-1}$  at 280 nm and this can be used to determine protein concentration. The antigen-binding protein sample was eluted from the PolyCAT A column with a 50-min linear gradient from Buffer A to Buffer B (see Table 1). Most of the single-chain proteins elute between 20 and 26 minutes when this gradient is used. This corresponds to an eluting solvent composition of approximately 70% Buffer A and 30% Buffer B. Most of the bivalent antigen-binding proteins elute later than 45 minutes, which correspond to over 90% Buffer B.

Figure 7 is a chromatogram depicting the separation of single-chain protein from bivalent CC49/212 protein, using the cation-exchange method just described. Peak 1, 27.32 minutes, represents the monomeric single-chain fraction. Peak 2, 55.52 minutes, represents the bivalent protein fraction.

Figure 8 is a chromatogram of the purified monomeric single-chain antigen-binding protein CC49/212 (Fraction 7 from Fig. 7) run on a Waters Protein-Pak 300SW gel filtration column. Monomer, with minor contaminates of dimer and trimer, is shown. Figure 9 is a chromatogram of the purified bivalent antigen-binding protein CC49/212 (Fraction 15 from Fig. 7) run on the same Waters Protein-Pak 300SW gel filtration column as used in Fig. 8.

- 26 -

TABLE 1					
PolyCAT A Cation-Exchange HPLC Gradients					
Time (min) <sup>a</sup>	Flow (ml/min)	Buffers <sup>b</sup>			C
		A	B		
Initial	15.0	100	0	0	
50.0	15.0	0	100	0	
55.0	15.0	0	100	0	
60.0	15.0	0	0	100	
63.0	15.0	0	0	100	
64.0	15.0	100	0	0	
67.0	15.0	100	0	0	

<sup>a</sup>Linear gradients are run between each time point.

<sup>b</sup>Buffer A, 60 mM MOPS, 0.5 mM Ca acetate, pH 6.0-6.4;  
Buffer B, 60 mM MOPS, 20mM Ca acetate, pH 7.5-8.0;  
Buffer C, 40 mM MOPS, 100 mM CaCl<sub>2</sub>, pH 7.5.

This purification procedure yielded multivalent antigen-binding proteins that are more than 95% pure as examined by SDS-PAGE and size exclusion HPLC. Modifications of the above procedure may be dictated by the isoelectric point of the particular multivalent antigen-binding protein being purified. Of the monomeric single-chain proteins that have been purified to date, all have had an isoelectric point (pI) between 8.0 and 9.5. However, it is possible that a multivalent antigen-binding protein may be produced with a pI of less than 7.0. In that case, an anion exchange column may be required for purification.

The CC49 monoclonal antibody was developed by Dr. Jeffrey Schlom's group, Laboratory of Tumor Immunology and Biology, National Cancer Institute. It binds specifically to the pan-carcinoma tumor antigen TAG-72. See Muraro, R. *et al.*, *Cancer Research* 48:4588-4596 (1988).

To determine the binding properties of the bivalent and monomeric CC49/212 antigen-binding proteins, a competition radioimmunoassay (RIA)

5 was set up in which a CC49 IgG (with two antigen binding sites) radiolabeled with  $^{125}\text{I}$  was competed against unlabeled CC49 IgG, or monovalent (fraction 7 in Figure 7) or bivalent (fraction 15 in Figure 7) CC49/212 antigen-binding protein for binding to the TAG-72 antigen on a human breast carcinoma extract. (See Figure 18). This competition RIA showed that the bivalent antigen-binding protein competed equally well for the antigen as did IgG, whereas the monovalent single-chain antigen-binding protein needed a ten-fold higher protein concentration to displace the IgG. Thus, the monovalent antigen-binding protein competes with about a ten-fold lower affinity for the antigen than does the bivalent IgG or bivalent antigen-binding protein. Figure 10 18 also shows the result of the competition RIA of a non-TAG-72 specific single-chain antigen-binding protein, the antifluorescein 4-4-20/212, which does not compete for binding.

### *Example 2*

15 *Process of Making Multivalent Antigen-Binding Proteins Using Dissociating Agents*

A. *Process Using Guanidine HCl and Ethanol*

20 Multivalent antigen-binding proteins were produced from purified single-chain proteins in the following way. First the purified single-chain protein at a concentration of 0.25-4 mg/ml was dialyzed against 0.5 moles/liter (M) guanidine hydrochloride (GuHCl), 20% ethanol (EtOH), in 0.05 M TRIS, 0.05 M KCl, 0.01 M  $\text{CaCl}_2$  buffer pH 8.0. This combination of dissociating agents is thought to disrupt the  $\text{V}_L/\text{V}_H$  interface, allowing the  $\text{V}_H$  of a first single-chain molecule to come into contact with a  $\text{V}_L$  from a second single-chain molecule. Other dissociating agents such as urea, and alcohols such as isopropanol or methanol should be substitutable for GuHCl and EtOH. Following the initial dialysis, the protein was dialyzed against the load buffer for the final HPLC purification step. Two separate purification protocols,

cation exchange and gel filtration chromatography, can be used to separate the single-chain protein monomer from the multivalent antigen-binding proteins. In the first method, monomeric and multivalent antigen-binding proteins were separated by using cation exchange HPLC chromatography, using a polyaspartate column (PolyCAT A). This was a similar procedure to that used in the final purification of the antigen-binding proteins as described in Example 1. The load buffer was 0.06 M MOPS, 0.001 M Calcium Acetate pH 6.4. In the second method, the monomeric and multivalent antigen-binding proteins were separated by gel filtration HPLC chromatography using as a load buffer 0.04 M MOPS, 0.10 M Calcium Acetate pH 7.5. Gel filtration chromatography separates proteins based on their molecular size.

Once the antigen-binding protein sample was loaded on the cation exchange HPLC column, a linear gradient was run between the load buffer (0.04 to 0.06 M MOPS, 0.000 to 0.001 M calcium acetate, 0 to 10% glycerol pH 6.0-6.4) and a second buffer (0.04 to 0.06 M MOPS, 0.01 to 0.02 M calcium acetate, 0 to 10% glycerol pH 7.5). It was important to have extensively dialyze the antigen-binding protein sample before loading it on the column. Normally, the conductivity of the sample is monitored against the dialysis buffer. Dialysis is continued until the conductivity drops below 600  $\mu$ S. Figure 11 shows the separation of the monomeric (27.83 min.) and bivalent (50.47 min.) forms of the CC49/212 antigen-binding protein by cation exchange. The chromatographic conditions for this separation were as follows: PolyCAT A column, 200 x 4.6mm, operated at 0.62 ml/min.; load buffer and second buffer as in Example 1; gradient program from 100 percent load buffer A to 0 percent load buffer A over 48 mins; sample was CC49/212, 1.66 mg/ml; injection volume 0.2 ml. Fractions were collected from the two peaks from a similar chromatogram and identified as monomeric and bivalent proteins using gel filtration HPLC chromatography as described below.

Gel filtration HPLC chromatography (TSK G2000SW column from Toyo Soda, Tokyo, Japan) was used to identify and separate monomeric single-chain and multivalent antigen-binding proteins. This procedure has been described by Fukano, *et al.*, *J. Chromatography* 166:47 (1978).

Multimerization (creation of multivalent protein from monomeric single-chain protein) was by treatment with 0.5 M GuHCl and 20% EtOH for the times indicated in Table 2A followed by dialysis into the chromatography buffer. Figure 12 shows the separation of monomeric (17.65 min.), bivalent (15.79 min.), trivalent (14.19 min.), and higher oligomers (shoulder at about 13.09 min.) of the B6.2/212 antigen-binding protein. The B6.2/212 single-chain antigen-binding protein is described in Colcher, D., *et al.*, *J. Nat. Cancer Inst.* 82:1191-1197 (1990)). This separation depicts the results of a 24-hour multimerization treatment of a 1.0 mg/ml B6.2/212 antigen-binding protein sample. The HPLC buffer used was 0.04 M MOPS, 0.10 M calcium acetate, 0.04 % sodium azide, pH 7.5.

Figure 13 shows the results of a 24-hour treatment of a 4.0 mg/ml CC49/212 antigen-binding protein sample, generating monomeric, bivalent and trivalent proteins at 16.91, 14.9, and 13.42 min., respectively. The HPLC buffer was 40 mM MOPS, 100 mM calcium acetate, pH 7.35. Multimerization treatment was for the times indicated in Table 2.

The results of Example 2A are shown in Table 2A. Table 2A shows the percentage of bivalent and other multivalent forms before and after treatment with 20% ethanol and 0.5M GuHCl. Unless otherwise indicated, percentages were determined using a automatic data integration software package.

- 30 -

**Table 2A**  
**Summary of the generation of bivalent and higher**  
**multivalent forms of B6.2/212 and CC49/212**  
**proteins using guanidine hydrochloride and ethanol**

protein	Time (hours)	Concentration (mg/ml)	% monomer dimer trimer multimers			
			monomer	dimer	trimer	multimers
CC49/212	0	0.25	86.7	11.6	1.7	0.0
	0	1.0 <sup>2</sup>	84.0	10.6	5.5	0.0
	0	4.0	70.0	17.1	12.9 <sup>1</sup>	0.0
	2	0.25 <sup>2</sup>	62.9	33.2	4.2	0.0
	2	1.0	24.2	70.6	5.1	0.0
	2	4.0	9.3	81.3	9.5	0.0
	24	0.25	16.0	77.6	6.4	0.0
	24	1.0	9.2	82.8	7.9	0.0
	24	4.0	3.7	78.2	18.1	0.0
B6.2/212	0	0.25	100.0	0.0	0.0	0.0
	0	1.0	100.0	0.0	0.0	0.0
	0	4.0	100.0	0.0	0.0	0.0
	2	0.25 <sup>2</sup>	98.1	1.9	0.0	0.0
	2	1.0	100.0	0.0	0.0	0.0
	2	4.0	90.0	5.5	1.0	0.0
	24	0.25	45.6	37.5	10.2	6.7
	24	1.0	50.8	21.4	12.3	15.0
	24	4.0	5.9	37.2	25.7	29.9

<sup>1</sup> Based on cut out peaks that were weighted.

<sup>2</sup> Average of two experiments.

### **B. Process Using Urea and Ethanol**

Multivalent antigen-binding proteins were produced from purified single-chain proteins in the following way. First the purified single-chain protein at a concentration of 0.25-1 mg/ml was dialyzed against 2M urea, 20% ethanol (EtOH), and 50mM Tris buffer pH 8.0, for the times indicated in Table 2B. This combination of dissociating agents is thought to disrupt the V<sub>L</sub>/V<sub>H</sub> interface, allowing the V<sub>H</sub> of a first single-chain molecule to come into contact with a V<sub>L</sub> from a second single-chain molecule. Other dissociating agents such as isopropanol or methanol should be substitutable for EtOH.

Following the initial dialysis, the protein was dialyzed against the load buffer for the final HPLC purification step.

Gel filtration HPLC chromatography (TSK G2000SW column from Toyo Soda, Tokyo, Japan) was used to identify and separate monomeric single-chain and multivalent antigen-binding proteins. This procedure has been described by Fukano, *et al.*, *J. Chromatography* 166:47 (1978).

The results of Example 2B are shown in Table 2B. Table 2B shows the percentage of bivalent and other multivalent forms before and after treatment with 20% ethanol and urea. Percentages were determined using an automatic data integration software package.

**Table 2B**

**Summary of the generation of bivalent and higher multivalent forms of  
B6.2/212 and CC49/212 proteins using urea and ethanol**

protein	Time (hours)	Concentration (mg/ml)	% multimers			
			monomer	dimer	trimer	multimers
B6.2	0	0.25	44.1	37.6	15.9	2.4
	0	1.0	37.7	33.7	19.4	9.4
	3	0.25	22.2	66.5	11.3	0.0
	3	1.0	13.7	69.9	16.4	0.0

### *Example 3*

#### *Determination of Binding Constants*

Three anti-fluorescein single-chain antigen-binding proteins have been constructed based on the anti-fluorescein monoclonal antibody 4-4-20. The three 4-4-20 single-chain antigen-binding proteins differ in the polypeptide linker connecting the  $V_H$  and  $V_L$  regions of the protein. The three linkers used were 202', 212 and 216 (see Table 3). Bivalent and higher forms of the 4-4-20 antigen-binding protein were produced by concentrating the purified monomeric single-chain antigen-binding protein in the cation exchange load buffer (0.06 M MOPS, 0.001 M calcium acetate pH 6.4) to 5 mg/ml. The

bivalent and monomeric forms of the 4-4-20 antigen-binding proteins were separated by cation exchange HPLC (polyaspartate column) using a 50 min. linear gradient between the load buffer (0.06 M MOPS, 0.001 M calcium acetate pH 6.4) and a second buffer (0.06 M MOPS, 0.02 M calcium acetate pH 7.5). Two 0.02 ml samples were separated, and fractions of the bivalent and monomeric protein peaks were collected on each run. The amount of protein contained in each fraction was determined from the absorbance at 278 nm from the first separation. Before collecting the fractions from the second separation run, each fraction tube had a sufficient quantity of  $1.03 \times 10^5$  M fluorescein added to it, such that after the fractions were collected a 1-to-1 molar ratio of protein-to-fluorescein existed. Addition of fluorescein stabilized the bivalent form of the 4-4-20 antigen-binding proteins. These samples were kept at 2°C (on ice).

The fluorescein dissociation rates were determined for each of these samples following the procedures described by Herron, J.N., in *Fluorescence Haptens: An Immunological Probe*, E.W. Voss, Ed., CRC Press, Boca Raton, FL (1984). A sample was first diluted with 20 mM HEPES buffer pH 8.0 to  $5.0 \times 10^{-8}$  M 4-4-20 antigen-binding protein. 560  $\mu$ l of the  $5.0 \times 10^{-8}$  M 4-4-20 antigen-binding protein sample was added to a cuvette in a fluorescence spectrophotometer equilibrated at 2°C and the fluorescence was read. 140  $\mu$ l of  $1.02 \times 10^{-5}$  M fluoresceinamine was added to the cuvette, and the fluorescence was read every 1 minute for up to 25 minutes (see Table 4).

The binding constants ( $K_b$ ) for the 4-4-20 single-chain antigen-binding protein monomers diluted in 20 mM HEPES buffer pH 8.0 in the absence of fluorescein were also determined (see Table 4).

The three polypeptide linkers in these experiments differ in length. The 202', 212 and 216 linkers are 12, 14 and 18 residues long, respectively. These experiments show that there are two effects of linker length on the 4-4-20 antigen-binding proteins: first, the shorter the linker length the higher the fraction of bivalent protein formed; second, the fluorescein dissociation rates of the monomeric single-chain antigen-binding proteins are effected more by the linker length than are the dissociation rates of the bivalent antigen-binding

proteins. With the shorter linkers 202' and 212, the bivalent antigen-binding proteins have slower dissociation rates than the monomers. Thus, the linkers providing optimum production and binding affinities for monomeric and bivalent antigen-binding proteins may be different. Longer linkers may be more suitable for monomeric single-chain antigen-binding proteins, and shorter linkers may be more suitable for multivalent antigen-binding proteins.

5

10

15

Table 3				
Linker Designs				
V <sub>L</sub>	Linker	V <sub>H</sub>	Linker Name	Reference
-KLEIE	GKSSGSGSESKS <sup>1</sup>	TOKLD-	202'	Bird <i>et al.</i>
-KLEIK	GSTSGSGKSSEGKG <sup>2</sup>	EVKLD-	212	Bedzyk <i>et al.</i>
-KLEIK	GSTSGSGKSSEGSGSTKG <sup>3</sup>	EVKLD-	216	This application
-KLVLK	GSTSGKPSEGKG <sup>4</sup>	EVKLD-	217	This application

(1) SEQ ID NO. 1

(2) SEQ ID NO. 2

(3) SEQ ID NO. 3

(4) SEQ ID NO. 4

Table 4				
Effects of Linkers on the SCA Protein Monomers and Dimers				
Linker				
	202'	212	216	
Monomer Fraction	0.47	0.66	0.90	
K <sub>a</sub>	$0.5 \times 10^9 \text{ M}^{-1}$	$1.0 \times 10^9 \text{ M}^{-1}$	$1.3 \times 10^9 \text{ M}^{-1}$	
Dissociation rate	$8.2 \times 10^{-3} \text{ s}^{-1}$	$4.9 \times 10^{-3} \text{ s}^{-1}$	$3.3 \times 10^{-3} \text{ s}^{-1}$	
Dimer Fraction	0.53	0.34	0.10	
Dissociation rate	$4.6 \times 10^{-3} \text{ s}^{-1}$	$3.5 \times 10^{-3} \text{ s}^{-1}$	$3.5 \times 10^{-3} \text{ s}^{-1}$	
Monomer/Dimer Dissociation rate ratio	1.8	1.4	0.9	

Example 4

## *Genetic Construction of a Mixed-Fragment Bivalent Antigen-Binding Protein*

The genetic constructions for one particular heterobivalent antigen-binding protein according to the Rearrangement model are shown in Figures 5 10A and 10B. Figure 10A is an amino acid and nucleotide sequence listing of the 4-4-20  $V_L$ /212/CC49  $V_H$  construct, coding for a single-chain protein with a 4-4-20  $V_L$ , linked via a 212 polypeptide linker to a CC49  $V_H$ . Figure 10B is a similar listing showing the CC49  $V_L$ /212/4-4-20  $V_H$  construct, coding for a single-chain protein with a CC49  $V_L$ , linked via a 212 linker to a 4-4-20  $V_H$ . These single-chain proteins may recombine according to the Rearrangement model to generate a heterobivalent protein comprising a CC49 10 antigen-binding site linked to a 4-4-20 antigen-binding site, as shown in Figure 5B.

"4-4-20  $V_L$ " means the variable region of the light chain of the 4-4-20 15 mouse monoclonal antibody (Bird, R.E. *et al.*, *Science* 242:423 (1988)). The number "212" refers to a specific 14-residue polypeptide linker that links the 4-4-20  $V_L$  and the CC49  $V_H$ . See Bedzyk, W.D. *et al.*, *J. Biol. Chem.* 265:18615-18620 (1990). "CC49  $V_H$ " is the variable region of the heavy 20 chain of the CC49 antibody, which binds to the TAG-72 antigen. The CC49 antibody was developed at The National Institutes of Health by Schlom, *et al.* *Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive With The Tumor-associated Glycoprotein 72 Antigen*, *Cancer Research* 48:4588-4596 (1988).

25 Insertion of the sequences shown in FIGS. 10A and 10B, by standard recombinant DNA methodology, into a suitable plasmid vector will enable one of ordinary skill in the art to transform a suitable host for subsequent expression of the single-chain proteins. See Maniatis *et al.*, *Molecular Cloning, A Laboratory Manual*, p. 104, Cold Spring Harbor Laboratory (1982), for general recombinant techniques for accomplishing the aforesaid 30 goals; see also U.S. Patent 4,946,778 (Ladner *et al.*) for a complete

description of methods of producing single-chain protein molecules by recombinant DNA technology.

To produce multivalent antigen-binding proteins from the two single-chain proteins, 4-4-20V<sub>L</sub>-212/CC49V<sub>H</sub> and CC49V<sub>L</sub>/212/4-4-20V<sub>H</sub>, the two single-chain proteins are dialyzed into 0.5 M GuHCl/20% EtOH being combined in a single solution either before or after dialysis. The multivalent proteins are then produced and separated as described in Example 2.

### *Example 5*

#### *Preparation of Multivalent Antigen-Binding Proteins by Chemical Cross-Linking*

Free cysteines were engineered into the C-terminal of the 4-4-20/212 single-chain antigen-binding protein, in order to chemically crosslink the protein. The design was based on the hinge region found in antibodies between the C<sub>H</sub>1 and C<sub>H</sub>2 regions. In order to try to reduce antigenicity in humans, the hinge sequence of the most common IgG class, IgG1, was chosen. The 4-4-20 Fab structure was examined and it was determined that the C-terminal sequence GluH216-ProH217-ArgH218, was part of the C<sub>H</sub>1 region and that the hinge between C<sub>H</sub>1 and C<sub>H</sub>2 starts with ArgH218 or GlyH219 in the mouse 4-4-20 IgG2A antibody. Figure 14 shows the structure of a human IgG. The hinge region is indicated generally. Thus the hinge from human IgG1 would start with LysH218 or SerH219. (See Table 5).

The C-terminal residue in most of the single-chain antigen-binding proteins described to date is the amino acid serine. In the design for the hinge region, the C-terminal serine in the 4-4-20/212 single-chain antigen-binding protein was made the first serine of the hinge and the second residue of the hinge was changed from a cysteine to a serine. This hinge cysteine normally forms a disulfide bridge to the C-terminal cysteine in the light chain.

TABLE 5

	218																	
	E	P	R	G	P	T	I	K	P		C	P	P	C	L	C	-	
	A	E	P	K		S	C	D	K	T	H	T	C	P	P	C	-	
	-	-	V	T	V	S												
	-	-	V	T	V	S	S	D	K	T	H	T	C					
	-	-	V	T	V	S	S	D	K	T	H	T	C	P	P	C		
5	IgG2A mouse <sup>1</sup>	IgG1 human <sup>2</sup>	SCA* <sup>3</sup>	SCA* Hinge design 1 <sup>4</sup>	SCA* Hinge design 2 <sup>5</sup>													

\* - single-chain antigen-binding protein

10 (1) SEQ ID NO. 5  
 (2) SEQ ID NO. 6  
 (3) SEQ ID NO. 7  
 (4) SEQ ID NO. 8  
 (5) SEQ ID NO. 9

15 There are possible advantages to having two C-terminal cysteines, for they might form an intramolecular disulfide bond, making the protein recovery easier by protecting the sulfurs from oxidation. The hinge regions were added by introduction of a BstE II restriction site in the 3'-terminus of the gene encoding the 4-4-20/212 single-chain antigen-binding protein (see Figures 15A-20 15B).

25 The monomeric single-chain antigen-binding protein containing the C-terminal cysteine can be purified using the normal methods of purifying a single-chain antigen-binding proteins, with minor modifications to protect the free sulfhydryls. The cross-linking could be accomplished in one of two ways. First, the purified single-chain antigen-binding protein could be treated with a mild reducing agent, such as dithiothreitol, then allowed to air oxidize to form a disulfide-bond between the individual single-chain antigen-binding proteins. This type of chemistry has been successful in producing heterodimers from whole antibodies (Nisonoff *et al.*, Quantitative Estimation 30 of the Hybridization of Rabbit Antibodies, *Nature* 4826:355-359 (1962); Brennan *et al.*, Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G<sub>1</sub> Fragments, *Science* 229:81-83 (1985)). Second, chemical crosslinking agents such as *bismaleimidehexane* could be used to cross-link two single-chain antigen-binding proteins by their 35 C-terminal cysteines. See Partis *et al.*, *J. Prot. Chem.* 2:263-277 (1983).

*Example 6**Genetic Construction of Bivalent Antigen-Binding Proteins*

Bivalent antigen-binding proteins can be constructed genetically and subsequently expressed in *E. coli* or other known expression systems. This can be accomplished by genetically removing the stop codons at the end of a gene encoding a monomeric single-chain antigen-binding protein and inserting a linker and a gene encoding a second single-chain antigen-binding protein. We have constructed a gene for a bivalent CC49/212 antigen-binding protein in this manner (see Figure 16). The CC49/212 gene in the starting expression plasmid is in an Aat II to Bam H1 restriction fragment (see Bird *et al.*, Single-Chain Antigen-Binding Proteins, *Science* 242:423-426 (1988); and Whitlow *et al.*, Single-Chain F<sub>v</sub> Proteins and Their Fusion Proteins, *Methods* 2:97-105 (1991)). The two stop codons and the Bam H1 site at the C-terminal end of the CC49/212 antigen-binding protein gene were replaced by a single residue linker (Ser) and an Aat II restriction site. The resulting plasmid was cut with Aat II and the purified Aat II to Aat II restriction fragment was ligated into Aat II cut CC49/212 single-chain antigen-binding protein expression plasmid. The resulting bivalent CC49/212 single-chain antigen-binding protein expression plasmid was transfected into an *E. coli* expression host that contained the gene for the cl857 temperature-sensitive repressor. Expression of single-chain antigen-binding protein in this system is induced by raising the temperature from 30°C to 42°C. Fig. 17 shows the expression of the divalent CC49/212 single-chain antigen-binding protein of Fig. 16 at 42°C, on an SDS-PAGE gel containing total *E. coli* protein. Lane 1 contains the molecular weight standards. Lane 2 is the uninduced *E. coli* production strain grown at 30°C. Lane 3 is divalent CC49/212 single-chain antigen-binding protein induced by growth at 42°C. The arrow shows the band of expressed divalent CC49/212 single-chain antigen-binding protein.

*Example 7**Construction, Purification, and Testing of 4-4-20/CC49 Heterodimer F<sub>v</sub> With 217 Linkers.*

The goals of this experiment were to produce, purify and analyze for activity a new heterodimer F<sub>v</sub> that would bind to both fluorescein and the pan-carcinoma antigen TAG-72. The design consisted of two polypeptide chains, which associated to form the active heterodimer F<sub>v</sub>. Each polypeptide chain can be described as a mixed single-chain F<sub>v</sub> (mixed sF<sub>v</sub>). The first mixed sF<sub>v</sub> (GX 8952) comprised a 4-4-20 variable light chain (V<sub>L</sub>) and a CC-49 variable heavy chain (V<sub>H</sub>) connected by a 217 polypeptide linker (Figure 19A). The second mixed sF<sub>v</sub> (GX 8953) comprised a CC-49 V<sub>L</sub> and a 4-4-20 V<sub>H</sub> connected by a 217 polypeptide linker (Figure 19B). The sequence of the 217 polypeptide linker is shown in Table 3. Construction of analogous CC49/4-4-20 heterodimers connected by a 212 polypeptide linker as described in Example 4.

*Results**A. Purification*

One 10-liter fermentation of each mixed sF<sub>v</sub> was grown on casein digest-glucose-salts medium at 32°C to an optical density at 600 nm of 15 to 20. The mixed sF<sub>v</sub> expression was induced by raising the temperature of the fermentation to 42°C for one hour. 277gm (wet cell weight) of *E. coli* strain GX 8952 and 233gm (wet cell weight) of *E. coli* strain GX 8953 were harvested in a centrifuge at 7000g for 10 minutes. The cell pellets were kept and the supernate discarded. The cell pellets were frozen at -20°C for storage.

2.55 liters of "lysis/wash buffer" (50mM Tris/ 200mM NaCl/ 1 mM EDTA, pH 8.0) was added to both of the mixed sFv's cell pellets, which were previously thawed and combined to give 510gm of total wet cell weight. After complete suspension of the cells they were then passed through a Gaulin homogenizer at 9000psi and 4°C. After this first pass the temperature increased to 23°C. The temperature was immediately brought down to 0°C using dry ice and methanol. The cell suspension was passed through the Gaulin homogenizer a second time and centrifuged at 8000 rpm with a Dupont GS-3 rotor for 60 minutes. The supernatant was discarded after centrifugation and the pellets resuspended in 2.5 liters of "lysis/wash buffer" at 4°C. This suspension was centrifuged for 45 minutes at 8000 rpm with the Dupont GS-3 rotor. The supernatant was again discarded and the pellet weighed. The pellet weight was 136.1 gm.

1300ml of 6M Guanidine Hydrochloride/50mM Tris/50mM KCl/10mM CaCl<sub>2</sub>, pH 8.0 at 4°C was added to the washed pellet. An overhead mixer was used to speed solubilization. After one hour of mixing, the heterodimer GuHCl extract was centrifuged for 45 minutes at 8000 rpm and the pellet was discarded. The 1425ml of heterodimer Fv 6M GuHCl extract was slowly added (16 ml/min) to 14.1 liters of "Refold Buffer" (50mM Tris/50mM KCl/10mM CaCl<sub>2</sub>, pH 8.0) under constant mixing at 4°C to give an approximate dilution of 1:10. Refolding took place overnight at 4°C.

After 17 hours of refolding the anti-fluorescein activity was checked by a 40% quenching assay, and the amount of active protein calculated. 150mg total active heterodimer Fv was found by the 40% quench assay, assuming a 54,000 molecular weight.

4 liters of prechilled (4°C) 190 proof ethanol was added to the 15 liters of refolded heterodimer with mixing for 3 hours. The mixture sat overnight at 4°C. A flocculent precipitate had settled to the bottom after this overnight treatment. The nearly clear solution was filtered through a Millipak-200 (0.22μ) filter so as to not disturb the precipitate. A 40% quench assay showed that 10% of the anti-fluorescein activity was recovered in the filtrate.

- 40 -

The filtered sample of heterodimer was dialyzed, using a Pellicon system containing 10,000 dalton MWCO membranes, with "dialysis buffer" 40mM MOPS/0.5mM Calcium Acetate (CaAc), pH 6.4 at 4°C. 20 liters of dialysis buffer was required before the conductivity of the retentate was equal to that of the dialysis buffer (~ 500 $\mu$ S). After dialysis the heterodimer sample was filtered through a Millipak-20 filter, 0.22 $\mu$ . After this step a 40% quench assay showed there was 8.8 mg of active protein.

The crude heterodimer sample was loaded on a Poly CAT A cation exchange column at 20ml/min. The column was previously equilibrated with 60mM MOPS, 1 mM CaAc pH 6.4, at 4°C, (Buffer A). After loading, the column was washed with 150ml of "Buffer A" at 15ml/min. A 50min linear gradient was performed at 15ml/min using "Buffer A" and "Buffer B" (60mM MOPS, 20mM CaAc pH 7.5 at 4°C). The gradient conditions are presented in Table 6. "Buffer C" comprises 60mM MOPS, 100mM CaCl<sub>2</sub>, pH 7.5.

Table 6

Time	%A	%B	%C	Flow
0:00	100.0	0.0	0.0	15ml/min
50:00	0.0	100.0	0.0	15ml/min
52:00	0.0	100.0	0.0	15ml/min
54:00	0.0	0.0	100.0	15ml/min
58:00	0.0	0.0	100.0	15ml/min
60:00	100.0	0.0	0.0	15ml/min

Approximately 50ml fractions were collected and analyzed for activity, purity, and molecular weight by size-exclusion chromatography. The fractions were not collected by peaks, so contamination between peaks is likely. Fractions 3 through 7 were pooled (total volume - 218ml), concentrated to 50ml and dialyzed against 4 liters of 60mM MOPS, 0.5mM CaAc pH 6.4 at 4°C overnight. The dialyzed pool was filtered through a 0.22 $\mu$  filter and

checked for absorbance at 280nm. The filtrate was loaded onto the PolyCAT A column, equilibrated with 60mM MOPS, 1 mM CaAc pH 6.4 at 4°C, at a flow rate of 10ml/min. Buffer B was changed to 60mM MOPS, 10mM CaAc pH 7.5 at 4°C. The gradient was run as in Table 6. The fractions were collected by peak and analyzed for activity, purity, and molecular weight. The chromatogram is shown in Figure 20. Fraction identification and analysis is presented in Table 7.

Table 7				
Fraction Analysis of the Heterodimer Fv protein				
	Fraction No.	A <sub>280</sub> reading	Total Volume (ml)	HPLC-SE Elution Time (min)
	2	0.161	36	20.525
	3	0.067	40	
	4	0.033	40	
10	5	0.178	45	19.133
	6	0.234	50	19.163
15	7	0.069	50	
	8	0.055	40	

Fractions 2 to 7 and the starting material were analyzed by SDS gel 20 electrophoresis, 4-20%. A picture and description of the gel is presented in Figure 21.

### ***B. HPLC Size Exclusion Results***

Fractions 2, 5, and 6 correspond to the three main peaks in Figure 20 and therefore were chosen to be analyzed by HPLC size exclusion. Fraction 25 2 corresponds to the peak that runs at 21.775 minutes in the preparative purification (Figure 20), and runs on the HPLC sizing column at 20.525 minutes, which is in the monomeric position (Figure 22A). Fractions 5 and 6 (30.1 and 33.455 minutes, respectively, in Figure 20) run on the HPLC sizing column (Figures 22B and 22C) at 19.133 and 19.163 minutes,

- 42 -

respectively (see Table 7). Therefore, both of these peaks could be considered dimers. 40% Quenching assays were performed on all fractions of this purification. Only fraction 5 gave significant activity. 2.4 mg of active CC49 4-4-20 heterodimer Fv was recovered in fraction 5, based on the Scatchard analysis described below.

5

### C. N-terminal sequencing of the fractions

The active heterodimer Fv fraction should contain both polypeptide chains. N-terminal sequence analysis showed that fractions 5 and 6 displayed N-terminal sequences consistent with the presence of both CC49 and 4-4-20 polypeptides and fraction 2 displayed a single sequence corresponding to the CC49/212/4-4-20 polypeptide only. We believe that fraction 6 was contaminated by fraction 5 (see Figure 20), since only fraction 5 had significant activity.

10

### D. Anti-fluorescein activity by Scatchard analysis

The fluorescein association constants ( $K_a$ ) were determined for fractions 5 and 6 using the fluorescence quenching assay described by Herron, J.N., in *Fluorescence Hapten: An Immunological Probe*, E.W. Voss, ed., CRC Press, Boca Raton, FL (1984). Each sample was diluted to approximately  $5.0 \times 10^{-8}$  M with 20 mM HEPES buffer pH 8.0. 590  $\mu$ l of the  $5.0 \times 10^{-8}$  M sample was added to a cuvette in a fluorescence spectrophotometer equilibrated at room temperature. In a second cuvette 590  $\mu$ l of 20 mM HEPES buffer pH 8.0 was added. To each cuvette was added 10  $\mu$ l of  $3.0 \times 10^{-7}$  M fluorescein in 20 mM HEPES buffer pH 8.0, and the fluorescence recorded. This is repeated until 140  $\mu$ l of fluorescein had been added. The resulting Scatchard analysis for fraction 5 shows a binding constant of  $1.16 \times 10^9$  M $^{-1}$  for fraction #5 (see Figure 23). This is very close to the 4-4-20/212 sFv constant of  $1.1 \times 10^9$  M $^{-1}$  (see Pantoliano *et al.*, *Biochemistry* 30:10117-10125 (1991)). The R intercept on the Scatchard analysis represents the fraction of active material. For fraction 5, 61 % of the

15

20

25

material was active. The graph of the Scatchard analysis on fraction 6 shows a binding constant of  $3.3 \times 10^8 \text{ M}^{-1}$  and 14% active. The activity that is present in fraction 6 is most likely contaminants from fraction 5.

#### *E. Anti-TAG-72 activity by competition ELISA*

5 The CC49 monoclonal antibody was developed by Dr. Jeffrey Schlom's group, Laboratory of Tumor Immunology and Biology, National Cancer Institute. It binds specifically to the pan-carcinoma tumor antigen TAG-72. See Muraro, R., *et al.*, *Cancer Research* 48:4588-4596 (1988).

10 To determine the binding properties of the bivalent CC49/4-4-20 Fv (fraction 5) and the CC49/212 sFv, a competition enzyme-linked immunosorbent assay (ELISA) was set up in which a CC49 IgG labeled with biotin was competed against unlabeled CC49/4-4-20 Fv and the CC49/212 sFv for binding to TAG-72 on a human breast carcinoma extract (see Figure 24). The amount of biotin-labeled CC49 IgG was determined using a preformed 15 complex with avidin and biotin coupled to horse radish peroxidase and O-phenylenediamine dihydrochloride (OPD). The reaction was stopped with 4N  $\text{H}_2\text{SO}_4$  (sulfuric acid), after 10 min. and the optical density read at 490nm. This competition ELISA showed that the bivalent CC49/4-4-20 Fv binds to the 20 TAG-72 antigen. The CC49/4-4-20 Fv needed a two hundred-fold higher protein concentration to displace the IgG than the single-chain Fv.

#### *Example 8*

#### *Cross-Linking Antigen-Binding Dimers*

25 We have chemically crosslinked dimers of 4-4-20/212 antigen-binding protein with the two cysteine C-terminal extension (4-4-20/212 CPPC single-chain antigen-binding protein) in two ways. In Example 5 we describe the design and genetic construction of the 4-4-20/212 CPPC single-chain antigen-binding protein (hinge design 2 in Table 5). Figure 15B shows the nucleic

- 44 -

acid and protein sequences of this protein. After purifying the 4-4-20/212 CPPC single-chain antigen-binding protein, using the methods described in Whitlow and Filpula, *Meth. Enzymol.* 2:97 (1991), dimers were formed by two methods. First, the free cysteines were mildly reduced with dithiothreitol (DTT) and then the disulfide-bonds between the two molecules were allowed to form by air oxidation. Second, the chemical crosslinker *bis*-maleimidehexane was used to produce dimers by crosslinking the free cysteines from two 4-4-20/212 CPPC single-chain antigen-binding proteins.

A 0.1 mg/ml solution of the 4-4-20/212 CPPC single-chain antigen-binding protein was mildly reduced using 1 mM DTT, 50 mM HEPES, 50 mM NaCl, 1 mM EDTA buffer pH 8.0 at 4°C. The samples were dialyzed against 50 mM HEPES, 50 mM NaCl, 1 mM EDTA buffer pH 8.0 at 4°C overnight, to allow the oxidation of free sulphhydryls to intermolecular disulfide-bonds. Figure 25 shows a non-reducing SDS-PAGE gel after the air oxidation; it shows that approximately 10% of the 4-4-20/212 CPPC protein formed dimers with molecular weights around 55,000 Daltons.

A 0.1 mg/ml solution of the 4-4-20/212 CPPC single-chain antigen-binding protein was treated with 2 mM *bis*-maleimidehexane. Unlike forming a disulfide-bond between two free cysteines in the previous example, the *bis*-maleimidehexane crosslinker material should be stable to reducing agents such as  $\beta$ -mercaptoethanol. Figure 26 shows that approximately 5% of the treated material produced dimer with a molecular weight of 55,000 Daltons on a reducing SDS-PAGE gel (samples were treated with  $\beta$ -mercaptoethanol prior to being loaded on the gel). We further purified the *bis*-maleimidehexane treated 4-4-20/212 CPPC protein on PolyCAT A cation exchange column after the protein had been extensively dialyzed against buffer A. Figure 26 shows that we were able to enhance the fraction containing the dimer to approximately 15%.

*Conclusions*

5

We have produced a heterodimer Fv from two complementary mixed sFv's which has been shown to have the size of a dimer of the sFv's. The N-terminal analysis has shown that the active heterodimer Fv contains two polypeptide chains. The heterodimer Fv has been shown to be active for both fluorescein and TAG-72 binding.

All publications cited herein are incorporated fully into this disclosure by reference.

10

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention and the following claims. As examples, the steps of the preferred embodiment constitute only one form of carrying out the process in which the invention may be embodied.

-46-  
SEQUENCE LISTING

**(1) GENERAL INFORMATION:**

(i) APPLICANT: Whitlow, Marc  
Wood, James F.  
Hardman, Karl  
Bird, Robert  
Filpula, David  
Rollence, Michele

(ii) TITLE OF INVENTION: Multivalent Antigen-Binding Proteins

(iii) NUMBER OF SEQUENCES: 23

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Sterne, Kessler, Goldstein & Fox  
(B) STREET: 1225 Connecticut Avenue  
(C) CITY: Washington  
(D) STATE: D.C.  
(E) COUNTRY: U.S.A.  
(F) ZIP: 20036

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: (to be assigned)  
(B) FILING DATE: Herewith  
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/796,936  
(B) FILING DATE: 25-NOV-1991

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Goldstein, Jorge A.  
(B) REGISTRATION NUMBER: 29,021  
(C) REFERENCE/DOCKET NUMBER: 0977.1906604

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (202) 833-7533  
(B) TELEFAX: (202) 833-8716

**(2) INFORMATION FOR SEQ ID NO:1:**

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser  
1 5 10

**(2) INFORMATION FOR SEQ ID NO:2:**

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly  
1 5 10

-47-

## (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Ser Gly Ser Thr  
1 5 10 15  
Lys Gly

## (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Gly Ser Thr Ser Gly Lys Pro Ser Glu Gly Lys Gly  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Leu Cys  
1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys  
1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Val Thr Val Ser  
1

- 48 -

## (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Val	Thr	Val	Ser	Ser	Asp	Lys	Thr	His	Thr	Cys
1										10

## (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: both

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Val	Thr	Val	Ser	Ser	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys
1											10		

## (2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 731 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..729

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GAC GTC GTT ATG ACT CAG ACA CCA CTA TCA CTT CCT GTT AGT CTA GGT Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly	48
1 . . . . . 5 10 . . . . . 15	
GAT CAA GCC TCC ATC TCT TGC AGA TCT AGT CAG AGC CTT GTC CAC AGT Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser	96
20 . . . . . 25 . . . . . 30	
AAT GGA AAC ACC TAT TTA CGT TGG TAC CTG CAG AAG CCA GGC CAG TCT Asn Gly Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser	144
35 . . . . . 40 . . . . . 45	
CCA AAG GTC CTG ATC TAC AAA GTT TCC AAC CGA TTT TCT GGG GTC CCA Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro	192
50 . . . . . 55 . . . . . 60	
GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA GAT TTC ACA CTC AAG ATC Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile	240
65 . . . . . 70 . . . . . 75 . . . . . 80	
AGC AGA GTG GAG GCT GAG GAT CTG GGA GTT TAT TTC TGC TCT CAA AGT Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser	288
85 . . . . . 90 . . . . . 95	
ACA CAT GTT CCG TGG ACG TTC GGT GGA GGC ACC AAG CTT GAA ATC AAA Thr His Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys	336
100 . . . . . 105 . . . . . 110	
GGT TCT ACC TCT GGT TCT GGT AAA TCC TCT GAA GGC AAA GGT CAG GTT Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly Gln Val	384
115 . . . . . 120 . . . . . 125	

- 49 -

CAG CTG CAG CAG TCT GAC GCT GAG TTG GTG AAA CCT GGG GCT TCA GTG	432
Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala Ser Val	
130 135 140	
AAG ATT TCC TGC AAG GCT TCT GGC TAC ACC TTC ACT GAC CAT GCA ATT	480
Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala Ile	
145 150 155 160	
CAC TGG GTG AAA CAG AAC CCT GAA CAG GGC CTG GAA TGG ATT GGA TAT	528
His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr	
165 170 175	
TTT TCT CCC GGA AAT GAT GAT TTT AAA TAC AAT GAG AGG TTC AAG GGC	576
Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly	
180 185 190	
AAG GCC ACA CTG ACT GCA GAC AAA TCC TCC AGC ACT GCC TAC GTG CAG	624
Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Val Gln	
195 200 205	
CTC AAC AGC CTG ACA TCT GAG GAT TCT GCA GTG TAT TTC TGT ACA AGA	672
Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Thr Arg	
210 215 220	
TCC CTG AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC	720
Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser	
225 230 235 240	
TAA TAG GAT CC	731
* * Asp	

## (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 243 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly	
1 5 10 15	
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser	
20 25 30	
Asn Gly Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser	
35 40 45	
Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro	
50 55 60	
Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile	
65 70 75 80	
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser	
85 90 95	
Thr His Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys	
100 105 110	
Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly Gln Val	
115 120 125	
Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala Ser Val	
130 135 140	
Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala Ile	
145 150 155 160	
His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr	
165 170 175	

-50-

Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly  
 180 185 190

Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Val Gln  
 195 200 205

Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Thr Arg  
 210 215 220

Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser  
 225 230 235 240

\* \* Asp

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 744 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..744

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GAC GTC GTG ATG TCA CAG TCT CCA TCC TCC CTA CCT GTG TCA GTT GGC 48  
 Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly  
 1 5 10 15

GAG AAG GTT ACT TTG AGC TGC AAG TCC AGT CAG AGC CTT TTA TAT AGT 96  
 Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser  
 20 25 30

GGT AAT CAA AAG AAC TAC TTG GCC TGG TAC CAG CAG AAA CCA GGG CAG 144  
 Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln  
 35 40 45

TCT CCT AAA CTG CTG ATT TAC TGG GCA TCC GCT AGG GAA TCT GGG GTC 192  
 Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser Gly Val  
 50 55 60

CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC TCC 240  
 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser  
 65 70 75 80

ATC AGC AGT GTG AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT CAG CAG 288  
 Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln  
 85 90 95

TAT TAT AGC TAT CCC CTC ACG TTC GGT GCT GGG ACC AAG CTT GTG CTG 336  
 Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu  
 100 105 110

AAA GGC TCT ACT TCC GGT AGC GGC AAA TCT TCT GAA GGT AAA GGT GAA 384  
 Lys Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly Glu  
 115 120 125

GTT AAA CTG GAT GAG ACT GGA GGA GGC TTG GTG CAA CCT GGG AGG CCC 432  
 Val Lys Leu Asp Glu Thr Gly Gly Leu Val Gln Pro Gly Arg Pro  
 130 135 140

ATG AAA CTC TCC TGT GTT GCC TCT GGA TTC ACT TTT AGT GAC TAC TGG 480  
 Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp  
 145 150 155 160

ATG AAC TGG GTC CGC CAG TCT CCA GAG AAA GGA CTG GAG TGG GTA GCA 528  
 Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala  
 165 170 175

CAA ATT AGA AAC AAA CCT TAT AAT TAT GAA ACA TAT TAT TCA GAT TCT 576  
 Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser  
 180 185 190

-51-

GTG AAA GGC AGA TTC ACC ATC TCA AGA GAT GAT TCC AAA AGT AGT GTC	624
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val	
195 - 200 205	
TAC CTG CAA ATG AAC AAC TTA AGA GTT GAA GAC ATG GGT ATC TAT TAC	672
Tyr Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly Ile Tyr Tyr	
210 - 215 220	
TGT ACG GGT TCT TAC TAT GGT ATG GAC TAC TGG GGT CAA GGA ACC TCA	720
Cys Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser	
225 230 235 240	
GTC ACC GTC TCC TAA TAA GGA TCC	744
Val Thr Val Ser * * Gly Ser	
245	

## (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 248 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly	
1 5 10 15	
Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser	
20 25 30	
Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln	
35 40 45	
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser Gly Val	
50 55 60	
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser	
65 70 75 80	
Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln	
85 90 95	
Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu	
100 105 110	
Lys Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly Glu	
115 120 125	
Val Lys Leu Asp Glu Thr Gly Gly Leu Val Gln Pro Gly Arg Pro	
130 135 140	
Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp	
145 150 155 160	
Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala	
165 170 175	
Gln Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser	
180 185 190	
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val	
195 200 205	
Tyr Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly Ile Tyr Tyr	
210 215 220	
Cys Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser	
225 230 235 240	
Val Thr Val Ser * * Gly Ser	
245	

-52-

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 761 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..756

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GAC GTC GTT ATG ACT CAG ACA CCA CTA TCA CTT CCT GTT AGT CTA GGT	48
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly	
1 5 10 15	
GAT CAA GCC TCC ATC TCT TGC AGA TCT AGT CAG AGC CTT GTA CAC AGT	96
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser	
20 25 30	
AAT GGA AAC ACC TAT TTA CGT TGG TAC CTG CAG AAG CCA GGC CAG TCT	144
Asn Gly Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser	
35 40 45	
CCA AAG GTC CTG ATC TAC AAA GTT TCC AAC CGA TTT TCT GGG GTC CCA	192
Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro	
50 55 60	
GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA GAT TTC ACA CTC AAG ATC	240
Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile	
65 70 75 80	
AGC AGA GTG GAG GCT GAG GAT CTG GGA GTT TAT TTC TGC TCT CAA AGT	288
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser	
85 90 95	
ACA CAT GTT CCG TGG ACG TTC GGT GGA GGC ACC AAG CTT GAA ATC AAA	336
Thr His Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys	
100 105 110	
GGT TCT ACC TCT GGT TCT AAA TCT TCT GAA GGT AAA GGT GAA GTT	384
Gly Ser Thr Ser Gly Ser Gly Ser Ser Glu Gly Lys Gly Glu Val	
115 120 125	
AAA CTG GAT GAG ACT GGA GGA GGC TTG GTG CAA CCT GGG AGG CCC ATG	432
Lys Leu Asp Glu Thr Gly Gly Leu Val Gln Pro Gly Arg Pro Met	
130 135 140	
AAA CTC TCC TGT GTT GCC TCT GGA TTC ACT TTT AGT GAC TAC TGG ATG	480
Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met	
145 150 155 160	
AAC TGG GTC CGC CAG TCT CCA GAG AAA GGA CTG GAG TGG GTA GCA CAA	528
Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln	
165 170 175	
ATT AGA AAC AAA CCT TAT AAT TAT GAA ACA TAT TAT TCA GAT TCT GTG	576
Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val	
180 185 190	
AAA GGC AGA TTC ACC ATC TCA AGA GAT GAT TCC AAA AGT AGT GTC TAC	624
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr	
195 200 205	
CTG CAA ATG AAC AAC TTA AGA GTT GAA GAC ATG GGT ATC TAT TAC TGT	672
Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly Ile Tyr Tyr Cys	
210 215 220	
ACG GGT TCT TAC TAT GGT ATG GAC TAC TGG GGT CAA GGA ACC TCG GTC	720
Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val	
225 230 235 240	

- 53 -

ACC GTC TCC AGT GAT AAG ACC CAT ACA TGC TAA TAGGATCC  
 Thr Val Ser Ser Asp Lys Thr His Thr Cys \*  
 245 250

761

## (2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 251 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly  
 1 5 10 15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser  
 20 25 30

Asn Gly Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
 35 40 45

Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro  
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser  
 85 90 95

Thr His Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys  
 100 105 110

Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly Glu Val  
 115 120 125

Lys Leu Asp Glu Thr Gly Gly Leu Val Gln Pro Gly Arg Pro Met  
 130 135 140

Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met  
 145 150 155 160

Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln  
 165 170 175

Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Ser Asp Ser Val  
 180 185 190

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr  
 195 200 205

Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly Ile Tyr Tyr Cys  
 210 215 220

Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val  
 225 230 235 240

Thr Val Ser Ser Asp Lys Thr His Thr Cys \*  
 245 250

## (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 770 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: both  
 (D) TOPOLOGY: both

- 54 -

## (ix) FEATURE:

(A)-NAME/KEY: CDS  
(B) LOCATION: 1..765

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GAC GTC GTT ATG ACT CAG ACA CCA CTA TCA CTT CCT GTC AGT CTA GGT	48
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly	
1 5 10 15	
GAT CAA GCC TCC ATC TCT TGC AGA TCT AGT CAG AGC CTT GTA CAC AGT	96
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser	
20 25 30	
AAT GGA AAC ACC TAT TTA CGT TGG TAC CTG CAG AAG CCA GGC CAG TCT	144
Asn Gly Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser	
35 40 45	
CCA AAG GTC CTG ATC TAC AAA GTT TCC AAC CGA TTT TCT GGG GTC CCA	192
Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro	
50 55 60	
GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA GAT TTC ACA CTC AAG ATC	240
Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile	
65 70 75 80	
AGC AGA GTG GAG GCT GAG GAT CTG GGA GTT TAT TTC TGC TCT CAA AGT	288
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser	
85 90 95	
ACA CAT GTT CCG TGG ACG TTC GGT GGA GGC ACC AAG CTT GAA ATC AAA	336
Thr His Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys	
100 105 110	
GGT TCT ACC TCT GGT TCT GGT AAA TCT TCT GAA GGT AAA GGT GAA GTT	384
Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly Glu Val	
115 120 125	
AAA CTG GAT GAG ACT GGA GGA GGC TTG GTG CAA CCT GGG AGG CCC ATG	432
Lys Leu Asp Glu Thr Gly Gly Leu Val Gln Pro Gly Arg Pro Met	
130 135 140	
AAA CTC TCC TGT GTT GCC TCT GGA TTC ACT TTT AGT GAC TAC TGG ATG	480
Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met	
145 150 155 160	
AAC TGG GTC CGC CAG TCT CCA GAG AAA GGA CTG GAG TGG GTA GCA CAA	528
Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln	
165 170 175	
ATT AGA AAC AAA CCT TAT AAT TAT GAA ACA TAT TAT TCA GAT TCT GTG	576
Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val	
180 185 190	
AAA GGC AGA TTC ACC ATC TCA AGA GAT GAT TCC AAA AGT AGT GTC TAC	624
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr	
195 200 205	
CTG CAA ATG AAC AAC TTA AGA GTT GAA GAC ATG GGT ATC TAT TAC TGT	672
Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly Ile Tyr Tyr Cys	
210 215 220	
ACG GGT TCT TAC TAT GGT ATG GAC TAC TGG GGT CAA GGA ACC TCG GTC	720
Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val	
225 230 235 240	
ACC GTC TCC AGT GAT AAG ACC CAT ACA TGC CCT CCA TGC TAA TAGGATCC	770
Thr Val Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys	
245 250 255	

- 55 -

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 254 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly  
 1 5 10 15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser  
 20 25 30

Asn Gly Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser  
 35 40 45

Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro  
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser  
 85 90 95

Thr His Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys  
 100 105 110

Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly Glu Val  
 115 120 125

Lys Leu Asp Glu Thr Gly Gly Leu Val Gln Pro Gly Arg Pro Met  
 130 135 140

Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met  
 145 150 155 160

Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln  
 165 170 175

Ile Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val  
 180 185 190

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr  
 195 200 205

Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly Ile Tyr Tyr Cys  
 210 215 220

Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val  
 225 230 235 240

Thr Val Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys \*  
 245 250

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1460 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1398

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

- 56 -

GAC GTC GTG ATG TCA CAG TCT CCA TCC TCC CTA CCT GTG TCA GTT GGC Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly 1 5 10 15	48
GAG AAG GTT ACT TTG AGC TGC AAG TCC AGT CAG AGC CTT TTA TAT AGT Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 20 25 30	96
GGT AAT CAA AAG AAC TAC TTG GCC TGG TAC CAG CAG AAA CCA GGG CAG Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45	144
TCT CCT AAA CTG CTG ATT TAC TGG GCA TCC GCT AGG GAA TCT GGG GTC Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser Gly Val 50 55 60	192
CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC TCC Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser 65 70 75 80	240
ATC AGC AGT GTG AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT CAG CAG Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln 85 90 95	288
TAT TAT AGC TAT CCC CTC ACG TTC GGT GCT GGG ACC AAG CTT GTG CTG Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu 100 105 110	336
AAA GGC TCT ACT TCC GGT AGC GGC AAA TCC TCT GAA GGC AAA GGT CAG Lys Gly Ser Thr Ser Gly Ser Gly Ser Ser Glu Gly Lys Gly Gln 115 120 125	384
GTT CAG CTG CAG CAG TCT GAC GCT GAG TTG GTG AAA CCT GGG GCT TCA Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala Ser 130 135 140	432
GTG AAG ATT TCC TGC AAG GCT TCT GGC TAC ACC TTC ACT GAC CAT GCA Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala 145 150 155 160	480
ATT CAC TGG GTG AAA CAG AAC CCT GAA CAG GGC CTG GAA TGG ATT GGA Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly 165 170 175	528
TAT TTT TCT CCC GGA AAT GAT GAT TTT AAA TAC AAT GAG AGG TTC AAG Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys 180 185 190	576
GGC AAG GCC ACA CTG ACT GCA GAC AAA TCC TCC AGC ACT GCC TAC GTG Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Val 195 200 205	624
CAG CTC AAC AGC CTG ACA TCT GAG GAT TCT GCA GTG TAT TTC TGT ACA Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Thr 210 215 220	672
AGA TCC CTG AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val 225 230 235 240	720
TCC TCA GAC GTC GTG ATG TCA CAG TCT CCA TCC TCC CTA CCT GTG TCA Ser Ser Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser 245 250 255	768
GTT GGC GAG AAG GTT ACT TTG AGC TGC AAG TCC AGT CAG AGC CTT TTA Val Gly Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu 260 265 270	816
TAT AGT GGT AAT CAA AAG AAC TAC TTG GCC TGG TAC CAG CAG AAA CCA Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro 275 280 285	864
GGG CAG TCT CCT AAA CTG CTG ATT TAC TGG GCA TCC GCT AGG GAA TCT Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser 290 295 300	912

- 57 -

GGG GTC CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT	960
Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr	
305 310 315 320	
CTC TCC ATC AGC AGT GTG AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT	1008
Leu Ser Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys	
325 330 335	
CAG CAG TAT TAT AGC TAT CCC CTC ACG TTC GGT GCT GGG ACC AAG CTT	1056
Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu	
340 345 350	
GTG CTG AAA GGC TCT ACT TCC GGT AGC GGC AAA TCC TCT GAA GGC AAA	1104
Val Leu Lys Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys	
355 360 365	
GGT CAG GTT CAG CTG CAG CAG TCT GAC GCT GAG TTG GTG AAA CCT GGG	1152
Gly Gln Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly	
370 375 380	
GCT TCA GTG AAG ATT TCC TGC AAG GCT TCT GGC TAC ACC TTC ACT GAC	1200
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp	
385 390 395 400	
CAT GCA ATT CAC TGG GTG AAA CAG AAC CCT GAA CAG GGC CTG GAA TGG	1248
His Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp	
405 410 415	
ATT GGA TAT TTT TCT CCC GGA AAT GAT GAT TTT AAA TAC AAT GAG AGG	1296
Ile Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg	
420 425 430	
TTC AAG GGC AAG GCC ACA CTG ACT GCA GAC AAA TCC TCC AGC ACT GCC	1344
Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala	
435 440 445	
TAC GTG CAG CTC AAC AGC CTG ACA TCT GAG GAT TCT GCA GTG TAT TTC	1392
Tyr Val Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe	
450 455 460	
TGT ACA AGA TCC CTG AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC	1440
Cys Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val	
465 470 475 480	
ACC GTC TCC TAA TAG GAT CC	1460
Thr Val Ser * * Asp	
485	

## (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 486 amino acids
- (B) TYPE: amino acid
- (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly	
1 5 10 15	
Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser	
20 25 30	
Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln	
35 40 45	
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser Gly Val	
50 55 60	
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser	
65 70 75 80	

- 58 -

Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Ser Cys Gln Gln  
85 90 95

Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu  
100 105 110

Lys Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly Gln  
115 120 125

Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala Ser  
130 135 140

Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala  
145 150 155 160

Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly  
165 170 175

Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys  
180 185 190

Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Val  
195 200 205

Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Thr  
210 215 220

Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val  
225 230 235 240

Ser Ser Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser  
245 250 255

Val Gly Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu  
260 265 270

Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro  
275 280 285

Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser  
290 295 300

Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Thr Asp Phe Thr  
305 310 315 320

Leu Ser Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys  
325 330 335

Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu  
340 345 350

Val Leu Lys Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys  
355 360 365

Gly Gln Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly  
370 375 380

Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp  
385 390 395 400

His Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp  
405 410 415

Ile Gly Tyr Phe Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg  
420 425 430

Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala  
435 440 445

Tyr Val Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe  
450 455 460

Cys Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val  
465 470 475 480

Thr Val Ser \* \* Asp  
485

-59-

## (2) INFORMATION FOR SEQ ID NO:20:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 725 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..723

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GAC GTC GTT ATG ACT CAG ACA CCA CTA TCA CTT CCT GTT AGT CTA GGT	48
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly	
1 5 10 15	
GAT CAA GCC TCC ATC TCT TGC AGA TCT AGT CAG AGC CTT GTA CAC AGT	96
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser	
20 25 30	
AAT GGA AAC ACC TAT TTA CGT TGG TAC CTG CAG AAG CCA GGC CAG TCT	144
Asn Gly Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser	
35 40 45	
CCA AAG GTC CTG ATC TAC AAA GTT TCC AAC CGA TTT TCT GGG GTC CCA	192
Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro	
50 55 60	
GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA GAT TTC ACA CTC AAG ATC	240
Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile	
65 70 75 80	
AGC AGA GTG GAG GCT GAG GAT CTG GGA GTT TAT TTC TGC TCT CAA AGT	288
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser	
85 90 95	
ACA CAT GTT CCG TGG ACG TTC GGT GGA GGC ACC AAG CTT GAA ATC AAA	336
Thr His Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys	
100 105 110	
GGT TCT ACC TCT GGT AAA CCA TCT GAA GGC AAA GGT CAG GTT CAG CTG	384
Gly Ser Thr Ser Gly Lys Pro Ser Glu Gly Lys Gly Gln Val Gln Leu	
115 120 125	
CAG CAG TCT GAC GCT GAG TTG GTG AAA CCT GGG GCT TCA GTG AAG ATT	432
Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile	
130 135 140	
TCC TGC AAG GCT TCT GGC TAC ACC TTC ACT GAC CAT GCA ATT CAC TGG	480
Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala Ile His Trp	
145 150 155 160	
GTG AAA CAG AAC CCT GAA CAG GGC CTG GAA TGG ATT GGA TAT TTT TCT	528
Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr Phe Ser	
165 170 175	
CCC GGA AAT GAT GAT TTT AAA TAC AAT GAG AGG TTC AAG GGC AAG GCC	576
Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly Lys Ala	
180 185 190	
ACA CTG ACT GCA GAC AAA TCC TCC AGC ACT GCC TAC GTG CAG CTC AAC	624
Thr Leu Thr Ala Asp Lys Ser Ser Thr Ala Tyr Val Gln Leu Asn	
195 200 205	
AGC CTG ACA TCT GAG GAT TCT GCA GTG TAT TTC TGT ACA AGA TCC CTG	672
Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Thr Arg Ser Leu	
210 215 220	

- 60 -

AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC TAA TAG	720
Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser * *	
225 230 235 240	
GAT CC	725
Asp	

## (2) INFORMATION FOR SEQ ID NO:21:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 241 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly	
1 5 10 15	
Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser	
20 25 30	
Asn Gly Asn Thr Tyr Leu Arg Trp Tyr Leu Gln Lys Pro Gly Gln Ser	
35 40 45	
Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro	
50 55 60	
Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile	
65 70 75 80	
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser	
85 90 95	
Thr His Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys	
100 105 110	
Gly Ser Thr Ser Gly Lys Pro Ser Glu Gly Lys Gly Gln Val Gln Leu	
115 120 125	
Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile	
130 135 140	
Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala Ile His Trp	
145 150 155 160	
Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr Phe Ser	
165 170 175	
Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly Lys Ala	
180 185 190	
Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Val Gln Leu Asn	
195 200 205	
Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Thr Arg Ser Leu	
210 215 220	
Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser * *	
225 230 235 240	

Asp

## (2) INFORMATION FOR SEQ ID NO:22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 738 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

-61-

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..738

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GAC GTC GTG ATG TCA CAG TCT CCA TCC TCC CTA CCT GTG TCA GTT GGC	48
Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly	
1 5 10 15	
GAG AAG GTT ACT TTG AGC TGC AAG TCC AGT CAG AGC CTT TTA TAT AGT	96
Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser	
20 25 30	
GGT AAT CAA AAG AAC TAC TTG GCC TGG TAC CAG CAG AAA CCA GGG CAG	144
Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln	
35 40 45	
TCT CCT AAA CTG CTG ATT TAC TGG GCA TCC GCT AGG GAA TCT GGG GTC	192
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser Gly Val	
50 55 60	
CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC TCC	240
Pro Asp Arg Phe Thr Gly Ser Gly Thr Asp Phe Thr Leu Ser	
65 70 75 80	
ATC AGC AGT GTG AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT CAG CAG	288
Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln	
85 90 95	
TAT TAT AGC TAT CCC CTC ACG TTC GGT GCT GGG ACC AAG CTT GTG CTG	336
Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu	
100 105 110	
AAA GGC TCT ACT TCC GGT AAA CCA TCT GAA GGT AAA GGT GAA GTT AAA	384
Lys Gly Ser Thr Ser Gly Lys Pro Ser Glu Gly Lys Gly Glu Val Lys	
115 120 125	
CTG GAT GAG ACT GGA GGA GGC TTG GTG CAA CCT GGG AGG CCC ATG AAA	432
Leu Asp Glu Thr Gly Gly Leu Val Gln Pro Gly Arg Pro Met Lys	
130 135 140	
CTC TCC TGT GTT GCC TCT GGA TTC ACT TTT AGT GAC TAC TGG ATG AAC	480
Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met Asn	
145 150 155 160	
TGG GTC CGC CAG TCT CCA GAG AAA GGA CTG GAG TGG GTA GCA CAA ATT	528
Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile	
165 170 175	
AGA AAC AAA CCT TAT AAT TAT GAA ACA TAT TAT TCA GAT TCT GTG AAA	576
Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val Lys	
180 185 190	
GGC AGA TTC ACC ATC TCA AGA GAT GAT TCC AAA AGT AGT GTC TAC CTG	624
Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu	
195 200 205	
CAA ATG AAC AAC TTA AGA GTT GAA GAC ATG GGT ATC TAT TAC TGT ACG	672
Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly Ile Tyr Tyr Cys Thr	
210 215 220	
GGT TCT TAC TAT GGT ATG GAC TAC TGG GGT CAA GGA ACC TCA GTC ACC	720
Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr	
225 230 235 240	
GTC TCC TAA TAA GGA TCC	738
Val Ser * * Gly Ser	
245	

## (2) INFORMATION FOR SEQ ID NO:23:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 246 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

- 62 -

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly  
1 5 10 15

Glu Lys Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser  
20 25 30

Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln  
35 40 45

Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser Gly Val  
50 55 60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser  
65 70 75 80

Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln  
85 90 95

Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu  
100 105 110

Lys Gly Ser Thr Ser Gly Lys Pro Ser Glu Gly Lys Gly Glu Val Lys  
115 120 125

Leu Asp Glu Thr Gly Gly Leu Val Gln Pro Gly Arg Pro Met Lys  
130 135 140

Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met Asn  
145 150 155 160

Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile  
165 170 175

Arg Asn Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val Lys  
180 185 190

Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu  
195 200 205

Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly Ile Tyr Tyr Cys Thr  
210 215 220

Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr  
225 230 235 240

Val Ser \* \* Gly Ser  
245

***What Is Claimed Is:***

1. A multivalent antigen-binding protein comprising two or more single-chain molecules, each single-chain molecule comprising:

(a) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;

5 (b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and

(c) a peptide linker linking said first and second polypeptides

(a) and (b) into said single-chain molecule.

2. The multivalent protein of claim 1 wherein said first polypeptide comprises the binding portion of the variable region of an antibody light chain, and said second polypeptide comprises the binding portion of the variable region of an antibody heavy chain.

10 3. The multivalent protein of claim 1 wherein said first polypeptide comprises the binding portion of the variable region of an antibody light chain, and said second polypeptide comprises the binding portion of the variable region of an antibody light chain.

15 4. The multivalent protein of claim 1 wherein said first polypeptide comprises the binding portion of the variable region of an antibody heavy chain, and said second polypeptide comprises the binding portion of the variable region of an antibody heavy chain.

20 5. The multivalent protein of claims 1, 2, 3, or 4 comprising a bivalent antigen-binding protein.

6. The multivalent protein of claim 5 comprising a heterobivalent antigen-binding protein.

7. The multivalent protein of claim 5 comprising a homobivalent antigen-binding protein.

8. A composition comprising a multivalent antigen-binding protein substantially free of single-chain molecules, wherein said multivalent protein comprises two or more single-chain molecules, each single-chain molecule comprising:

- (a) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and
- (c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain molecule.

9. The composition of claim 8 wherein said first polypeptide comprises the binding portion of the variable region of an antibody light chain, and said second polypeptide comprises the binding portion of the variable region of an antibody heavy chain.

10. The composition of claim 8 wherein said first polypeptide comprises the binding portion of the variable region of an antibody light chain, and said second polypeptide comprises the binding portion of the variable region of an antibody light chain.

11. The composition of claim 8 wherein said first polypeptide comprises the binding portion of the variable region of an antibody heavy chain, and said second polypeptide comprises the binding portion of the variable region of an antibody heavy chain.

25 12. The composition of claims 8, 9, 10, or 11, comprising a bivalent antigen-binding protein substantially free of single-chain molecules.

13. The composition of claim 12 wherein said bivalent protein is heterobivalent.

14. The composition of claim 12 wherein said bivalent protein is homobivalent.

5 15. An aqueous composition comprising an excess of multivalent antigen-binding protein over single-chain molecules, said multivalent protein comprising two or more single-chain molecules, each single-chain molecule comprising:

10 (a) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;

(b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and

(c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

15 16. The aqueous composition of claim 15 wherein at least one of said single-chain molecules comprises:

20 (a) a first polypeptide comprising the binding portion of the variable region of an antibody light chain;

(b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy chain; and

(c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

17. The aqueous composition of claim 15 wherein at least one of said single-chain molecules comprises:

25 (a) a first polypeptide comprising the binding portion of the variable region of an antibody light chain;

(b) a second polypeptide comprising the binding portion of the variable region of an antibody light chain; and

(c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

18. The composition of claim 15 wherein at least one of said single-chain molecules comprises:

5 (a) a first polypeptide comprising the binding portion of the variable region of an antibody heavy chain;

(b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy chain; and

(c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

10 19. A method of producing a multivalent antigen-binding protein, comprising the steps of:

15 (a) producing a composition comprising multivalent antigen-binding protein and single-chain molecules, each single-chain molecule comprising:

(i) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;

(ii) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and

20 (iii) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain molecule;

(b) separating said multivalent protein from said single-chain molecules; and

(c) recovering said multivalent protein.

25 20. The method of claim 19 wherein separating said multivalent protein from said single-chain molecules comprises utilizing cation exchange chromatography.

21. The method of claim 19 wherein separating said multivalent protein from said single-chain molecules comprises utilizing gel filtration chromatography.

22. A method of producing a multivalent antigen-binding protein comprising the steps of:

(a) producing a composition comprising single-chain molecules, each single-chain molecule comprising:

(i) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;

(ii) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and

(iii) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain molecule;

(b) dissociating said single-chain molecules;

(c) re-associating said single-chain molecules;

(d) separating multivalent antigen-binding proteins from said single-chain molecules; and

(e) recovering said multivalent proteins.

23. The method of claim 22 wherein said dissociation is caused by dialysis against a dissociating solution.

24. The method of claim 22 wherein said reassociation is caused by dialysis against a refolding solution or a refolding agent.

25. A method of producing a multivalent antigen-binding protein, comprising the step of cross-linking at least two single-chain molecules to each other, each single-chain molecule comprising:

(a) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;

- (b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and
- (c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain molecule.

5 26. The method of claim 25 wherein said cross-linking is effected by chemical means.

27. A method of producing a multivalent antigen-binding protein, comprising the steps of:

- (a) producing a composition comprising single-chain molecules, each single-chain molecule comprising:
  - (i) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
  - (ii) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and
  - (iii) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain molecule;
- (b) concentrating said single-chain molecules;
- (c) separating said multivalent protein from said single-chain molecules; and
- 20 (d) recovering said multivalent protein.

28. The method of claim 27 wherein said concentrating step occurs from approximately 0.5 mg/ml single-chain molecule to the concentration at which precipitation starts.

29. A method of detecting an antigen in or suspected of being in a sample, which comprises:

- (a) contacting said sample with the multivalent antigen-binding protein of claim 1; and

(b) detecting whether said multivalent antigen-binding protein has bound to said antigen.

30. A method of imaging the internal structure of an animal, comprising administering to said animal an effective amount of a labeled form of the multivalent antigen-binding protein of claim 1 and measuring detectable radiation associated with said animal.

5 31. A composition comprising an association of a multivalent antigen-binding protein as claimed in any one of claims 1-4, 8-11, or 15-18 with a therapeutically or diagnostically effective agent.

10 32. A single-chain protein comprising:  
(a) a first polypeptide comprising the binding portion of the variable region of an antibody light chain;  
(b) a second polypeptide comprising the binding portion of the variable region of an antibody light chain;  
15 (c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

20 33. A single-chain protein comprising:  
(a) a first polypeptide comprising the binding portion of the variable region of an antibody heavy chain;  
(b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy chain;  
25 (c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

34. A single-chain protein comprising:  
25 (a) a first polypeptide comprising the  $V_L$  or  $V_H$  of a CC49 monoclonal antibody;

- 70 -

(b) a second polypeptide comprising the  $V_L$  or  $V_H$  of a CC49 monoclonal antibody; and

(c) a peptide linker linking said first and second polypeptides

(a) and (b) into said single-chain protein.

5 35. The single-chain protein of claim 34 wherein said linker is selected from the group consisting of the 202', 212, 216, and 217 linkers.

36. A single-chain protein comprising:

(a) a first polypeptide comprising the  $V_L$  or  $V_H$  of a CC49 monoclonal antibody;

10 (b) a second polypeptide comprising the  $V_L$  or  $V_H$  of a 4-4-20 monoclonal antibody; and

(c) a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

15 37. The single-chain protein of claim 36 wherein said linker is selected from the group consisting of the 202', 212, 216, and 217 linkers.

38. A genetic sequence which codes for the single-chain protein of claim 32, comprising:

20 (a) a DNA sequence coding for a first polypeptide comprising the binding portion of the variable region of an antibody light chain;

(b) a DNA sequence coding for a second polypeptide comprising the binding portion of the variable region of an antibody light chain;

(c) a DNA sequence coding for a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

25 39. A genetic sequence which codes for the single-chain protein of claim 33, comprising:

(a) a DNA sequence coding for a first polypeptide comprising the binding portion of the variable region of an antibody heavy chain;

5 (b) a DNA sequence coding for a second polypeptide comprising the binding portion of the variable region of an antibody heavy chain;

(c) a DNA sequence coding for a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

40. A genetic sequence which codes for the single-chain protein of  
10 claim 34, comprising:

(a) a DNA sequence coding for the  $V_L$  or  $V_H$  of a CC49 monoclonal antibody;

(b) a DNA sequence coding for the  $V_L$  or  $V_H$  of a CC49 monoclonal antibody;

15 (c) a DNA sequence coding for a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

41. The genetic sequence of claim 40 wherein said DNA sequence codes for a peptide linker selected from the group consisting of the 202', 212, 216, and 217 linkers.

20 42. A genetic sequence which codes for the single-chain protein of  
claim 36, comprising:

(a) a DNA sequence coding for the  $V_L$  or  $V_H$  of a CC49 monoclonal antibody;

(b) a DNA sequence coding for the  $V_L$  or  $V_H$  of a 4-4-20 monoclonal antibody;

25 (c) a DNA sequence coding for a peptide linker linking said first and second polypeptides (a) and (b) into said single-chain protein.

43. The genetic sequence of claim 42 wherein said DNA sequence codes for a peptide linker selected from the group consisting of the 202', 212, 216, and 217 linkers.

44. A multivalent single-chain antigen-binding protein comprising:

- 5 (a) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (c) a peptide linker linking said first and second polypeptides (a) and (b) into said multivalent protein;
- (d) a third polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (e) a fourth polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- 10 (f) a peptide linker linking said third and fourth polypeptides (d) and (e) into said multivalent protein; and
- (g) a peptide linker linking said second and third polypeptides (b) and (d) into said multivalent protein.

45. A multivalent single-chain antigen-binding protein comprising:

- 20 (a) a first polypeptide comprising the binding portion of the variable region of an antibody light chain;
- (b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy chain;
- (c) a peptide linker linking said first and second polypeptides (a) and (b) into said multivalent protein;
- (d) a third polypeptide comprising the binding portion of the variable region of an antibody light chain;
- (e) a fourth polypeptide comprising the binding portion of the variable region of an antibody heavy chain;

- (f) a peptide linker linking said third and fourth polypeptides (d) and (e) into said multivalent protein; and
- (g) a peptide linker linking said second and third polypeptides (b) and (d) into said multivalent protein.

5 46. A genetic sequence which codes for the multivalent antigen-binding protein of claim 44 or 45, comprising:

- (a) a DNA sequence coding for a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (b) a DNA sequence coding for a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (c) a DNA sequence coding for a peptide linker linking said first and second polypeptides (a) and (b) into said multivalent protein
- (d) a DNA sequence coding for a third polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (e) a DNA sequence coding for a fourth polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (f) a DNA sequence coding for a peptide linker linking said third and fourth polypeptides (d) and (e) into said multivalent protein; and
- (g) a DNA sequence coding for a peptide linker linking said second and third polypeptides (b) and (d) into said multivalent protein.

25 47. A replicable cloning or expression vehicle comprising the DNA sequence of any one of claims 38-43.

48. The vehicle of claim 47 which is a plasmid.

49. A host cell transformed with the vehicle of claim 47.

50. The host cell of claim 49 which is a bacterial cell, a yeast cell or other fungal cell, or a mammalian cell line.

51. A method of producing a multivalent antigen-binding protein comprising two or more single-chain molecules, each single-chain molecule comprising:

- (a) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain; and
- (c) a peptide linker linking said first and second polypeptides

10 (a) and (b) into said single-chain molecule, said method comprising:

- (i) providing a genetic sequence coding for said single-chain molecule;
- (ii) transforming one or more host cells with said sequence;
- (iii) expressing said sequence in said host or hosts; and
- (iv) recovering a multivalent protein from said host or hosts.

20 52. A method of producing a multivalent single-chain antigen-binding protein comprising two or more single-chain molecules, each single-chain molecule comprising:

- (a) a first polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (b) a second polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;
- (c) a peptide linker linking said first and second polypeptides

(a) and (b) into said multivalent protein;

- (d) a third polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;

(e) a fourth polypeptide comprising the binding portion of the variable region of an antibody heavy or light chain;

(f) a peptide linker linking said third and fourth polypeptides

(d) and (e) into said multivalent protein; and

5 (g) a peptide linker linking said second and third polypeptides (b) and (d) into said multivalent protein, said method comprising:

(i) providing a genetic sequence coding for said single-chain molecule;

10 (ii) transforming one or more host cells with said sequence;

(iii) expressing said sequence in said host or hosts;

and

(iv) recovering a multivalent protein from said host or hosts.

15 53. The method of claim 51 or 52 wherein recovering said multivalent protein comprises separating said multivalent protein from said single-chain molecules.

54. The method of claim 51 or 52 wherein recovering said multivalent protein comprises:

20 (a) dissociating said single-chain molecules;

(b) re-associating said single-chain molecules;

(c) separating multivalent antigen-binding proteins from said single-chain molecules; and

(d) recovering said multivalent proteins.

25 55. The method of claim 51 or 52 which further comprises purifying said recovered multivalent protein.

56. The method of claim 51 or 52 wherein said host cell is a bacterial cell, a yeast cell or other fungal cell, or a mammalian cell line.

57. The method of claim 56 wherein said host cell is *E. coli* or *Bacillus subtilis*.

58. The multivalent antigen-binding protein of claim 1 in detectably-labelled form.

5 59. In an immunoassay method which utilizes an antibody in detectably-labelled form, the improvement comprising using the multivalent protein of claim 58 instead of said antibody.

60. The immunoassay of claim 59 wherein said immunoassay is a competitive immunoassay.

10 61. The immunoassay of claim 59 wherein said immunoassay is a sandwich immunoassay.

62. In an immunotherapeutic method which utilizes an antibody conjugated to a therapeutic agent, the improvement comprising using the multivalent protein of claim 1 instead of said antibody.

15 63. In a method of immunoaffinity purification which utilizes an antibody therefor, the improvement which comprises using the molecule of claim 1 instead of said antibody.

1/39




FIG. 1A




FIG. 1B




FIG. 1C

2/39




FIG.2A




FIG.2B




FIG.2C

3/39




FIG.3A




FIG.3B




FIG.3C

4/39




FIG.4A






FIG.4B

5/39



ANTI-B VL - ANTI-A VH



ANTI-A VL - ANTI-B VH

FIG.5A




FIG.5B




FIG.5C

6/39




FIG. 6A





FIG. 6B

7/39



8/39




FIG. 8

9/39




FIG. 9

10/39

4-4-20  $V_L$ /212/CC49  $V_H$  gene

4-4-20  $V_L$  10 20  
 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser  
GAC GTC GTT ATG ACT CAG ACA CCA CTA TCA CTT CCT GTT AGT CTA GGT GAT CAA GCC TCC  
 Aat II

30 40  
 Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu Arg Trp  
 ATC TCT TGC AGA TCT AGT CAG AGC CTT GTA CAC AGT AAT GGA AAC ACC TAT TTA CGT TGG

50 60  
 Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe  
 TAC CTG CAG AAG CCA GGC CAG TCT CCA AAG GTC CTG ATC TAC AAA GTT TCC AAC CGA TTT

70 80  
 Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 TCT GGG GTC CCA GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA GAT TTC ACA CTC AAG ATC

90 100  
 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro  
 AGC AGA GTG GAG GCT GAG GAT CTG GGA GTT TAT TTC TGC TCT CAA AGT ACA CAT GTT CCG

110 212 Linker 120  
 Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Gly Ser Thr Ser Gly Ser Gly Lys  
 TGG ACG TTC GGT GGA GGC ACC AAG CTT GAA ATC AAA GGT TCT ACC TCT GGT TCT GGT AAA  
 Hind III

130 140  
Ser Ser Glu Gly Lys Gly Gln Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro  
TCC TCT GAA GGC AAA GGT CAG GTT CAG CTG CAG CAG TCT GAC GCT GAG TTG GTG AAA CCT  
 PvuII PstI

150 160  
 Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala Ile  
 GGG GCT TCA GTG AAG ATT TCC TGC AAG GCT TCT GGC TAC ACC TTC ACT GAC CAT GCA ATT

170 180  
 His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr Phe Ser Pro Gly  
 CAC TGG GTG AAA CAG AAC CCT GAA CAG GGC CTG GAA TGG ATT GGA TAT TTT TCT CCC GGA

FIG.10A

11/39

4-4-20  $V_L$  /212/CC49  $V_H$  gene

190	200
Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys	
AAT GAT GAT TTT AAA TAC AAT GAG AGG TTC AAG GGC AAG GCC ACA CTG ACT GCA GAC AAA	
210	220
Ser Ser Ser Thr Ala Tyr Val Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr	
TCC TCC AGC ACT GCC TAC GTG CAG CTC AAC AGC CTG ACA TCT GAG GAT TCT GCA GTG TAT	
230	240
TTC TGT ACA AGA TCC CTG AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC	
Phe Cys Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser	

\*\*\* \*\*\* Asp  
TAA TAG GAT CC

Bam H1

FIG.10A(CONT.)

12/39

CC49 VL/212/4-4-20 VH gene

CC49 VL 10 20  
 Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr  
GAC GTC GTG ATG TCA CAG TCT CCA TCC CTA CCT GTG TCA GTT GGC GAG AAG GTT ACT  
Aat II

30 40  
 Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala  
 TTG AGC TGC AAG TCC AGT CAG AGC CTT TTA TAT AGT GGT AAT CAA AAG AAC TAC TTG GCC

50 60  
 Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg  
 TGG TAC CAG CAG AAA CCA GGG CAG TCT CCT AAA CTG CTG ATT TAC TGG GCA TCC GCT AGG

70 80  
 Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser  
 GAA TCT GGG GTC CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC TCC

90 100  
 Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr  
 ATC AGC AGT GTG AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT CAG CAG TAT TAT AGC TAT

110 212 Linker 120  
 Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu Lys Gly Ser Thr Ser Gly Ser Gly  
 CCC CTC ACG TTC GGT GGG ACC AAG CTT GTG CTG AAA GGC TCT ACT TCC GGT AGC GGC  
Hind III

4-4-20 VH 140  
Lys Ser Ser Glu Gly Lys Gly Glu Val Lys Leu Asp Glu Thr Gly Gly Leu Val Gln  
 AAA TCT TCT GAA GGT AAA GGT GAA GTT AAA CTG GAT GAG ACT GGA GGA GGC TTG GTG CAA

150 160  
 Pro Gly Arg Pro Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp  
 CCT GGG AGG CCC ATG AAA CTC TCC TGT GTT GCC TCT GGA TTC ACT TTT AGT GAC TAC TGG

170 180  
 Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn  
 ATG AAC TGG GTC CGC CAG TCT CCA GAG AAA GGA CTG GAG TGG GTA GCA CAA ATT AGA AAC

FIG.10B

13/39

CC49  $V_L$  / 212/4-4-20  $V_H$  gene

190 200  
Lys Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser  
AAA CCT TAT AAT TAT GAA ACA TAT TAT TCA GAT TCT GTG AAA GGC AGA TTC ACC ATC TCA

210 220  
Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met  
AGA GAT GAT TCC AAA AGT AGT GTC TAC CTG CAA ATG AAC AAC TTA AGA GTT GAA GAC ATG

230 240  
Gly Ile Tyr Tyr Cys Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser  
GGT ATC TAT TAC TGT ACG GGT TCT TAC TAT GGT ATG GAC TAC TGG GGT CAA GGA ACC TCA

Val Thr Val Ser \* \* Gly Ser  
GTC ACC GTC TCC TAA TAA GGG TCC  
Bam H1

FIG.10B(CONT.)

14/39




FIG. 11

15/39




FIG. 12

16/39




FIG. 13




FIG. 14

18/39

4-4-20/212

protein with single cysteine hinge

4-4-20 VL

10

20

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser  
GAC GTC GTT ATG ACT CAG ACA CCA CTA TCA CTT CCT GTT AGT CTA GGT GAT CAA GCC TCC  
Aat II

30

40

Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu Arg Trp  
 ATC TCT TGC AGA TCT AGT CAG AGC CTT GTA CAC AGT AAT GGA AAC ACC TAT TTA CGT TGG

50

60

Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe  
 TAC CTG CAG AAG CCA GGC CAG TCT CCA AAG GTC CTG ATC TAC AAA GTT TCC AAC CGA TTT

70

80

Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 TCT GGG GTC CCA GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA GAT TTC ACA CTC AAG ATC

90

100

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro  
 AGC AGA GTG GAG GCT GAG GAT CTG GGA GTT TAT TTC TGC TCT CAA AGT ACA CAT GTT CCG

110

212 Linker

120

Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Gly Ser Thr Ser Gly Ser Gly Lys  
 TGG ACG TTC GGT GGA GGC ACC AAG CTT GAA ATC AAA GGT TCT ACC TCT GGT TCT GGT AAA  
Hind III

4-4-20 VH

140

Ser Ser Glu Gly Lys Gly Glu Val Lys Leu Asp Glu Thr Gly Gly Leu Val Gln Pro  
TCT TCT GAA GGT AAA GGT GAA GTT AAA CTG GAT GAG ACT GGA GGA GGC TTG GTG CAA CCT

150

160

Gly Arg Pro Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met  
 GGG AGG CCC ATG AAA CTC TCC TGT GTT GCC TCT GGA TTC ACT TTT AGT GAC TAC TGG ATG

170

180

Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys  
 AAC TGG GTC CGC CAG TCT CCA GAG AAA GGA CTG GAG TGG GTA GCA CAA ATT AGA AAC AAA

FIG. 15A

19/39

4-4-20/212

protein with single cysteine hinge

190 200  
Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg  
CCT TAT AAT TAT GAA ACA TAT TAT TCA GAT TCT GTG AAA GGC AGA TTC ACC ATC TCA AGA

210 220  
Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly  
GAT GAT TCC AAA AGT AGT GTC TAC CTG CAA ATG AAC AAC TTA AGA GTT GAA GAC ATG GGT

230 240  
Ile Tyr Tyr Cys Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val  
ATC TAT TAC TGT ACG GGT TCT TAC TAT GGT ATG GAC TAC TGG GGT CAA GGA ACC TCG GTC  
Bst EII

Hinge 250  
Thr Val Ser Ser Asp Lys Thr His Thr Cys \*\*\* \*\*\*  
ACC GTC TCC AGT GAT AAG ACC CAT ACA TGC TAA TAG GAT CC  
Bam H1  
pGx 5532, Gx 8932

FIG.15A(CONT.)

20/39

4-4-20/212 protein with two cysteine hinge

4-4-20 VL	10	20	
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser			
<u>GAC GTC</u> GTT ATG ACT CAG ACA CCA CTA TCA CTT CCT GTT AGT CTA GGT GAT CAA GCC TCC			
Aat II			
	30	40	
Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu Arg Trp			
ATC TCT TGC AGA TCT AGT CAG AGC CTT GTC CAC AGT AAT GGA AAC ACC TAT TTA CGT TGG			
	50	60	
Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe			
TAC CTG CAG AAG CCA GGC CAG TCT CCA AAG GTC CTG ATC TAC AAA GTT TCC AAC CGA TTT			
	70	80	
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile			
TCT GGG GTC CCA GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA GAT TTC ACA CTC AAG ATC			
	90	100	
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro			
AGC AGA GTG GAG GCT GAG GAT CTG GGA GTT TAT TTC TGC TCT CAA AGT ACA CAT GTT CCG			
	110	212 Linker	120
Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys <u>Gly Ser Thr Ser Gly Ser Gly Lys</u>			
TGG ACG TTC GGT GGA GGC ACC <u>AAG CTT GAA ATC AAA GGT TCT ACC TCT GGT TCT GGT AAA</u>			
Hind III			
4-4-20 VH	130		140
<u>Ser Ser Glu Gly Lys Gly</u> Glu Val Lys Leu Asp Glu Thr Gly Gly Leu Val Gln Pro			
TCT TCT GAA GGT AAA GGT GAA GTT AAA CTG GAT GAG ACT GGA GGA GGC TTG GTG CAA CCT			
	150		160
Gly Arg Pro Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met			
GGG AGG CCC ATG AAA CTC TCC TGT GTT GCC TCT GGA TTC ACT TTT AGT GAC TAC TGG ATG			
	170		180
Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys			
AAC TGG GTC CGC CAG TCT CCA GAG AAA GGA CTG GAG TGG GTA GCA CAA ATT AGA AAC AAA			

FIG.15B

21/39

4-4-20/212 protein with two cysteine hinge

190 200  
Pro Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg  
CCT TAT AAT TAT GAA ACA TAT TAT TCA GAT TCT GTG AAA GGC AGA TTC ACC ATC TCA AGA

210 220  
Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly  
GAT GAT TCC AAA AGT AGT GTC TAC CTG CAA ATG AAC AAC TTA AGA GTT GAA GAC ATG GGT

230 240  
Ile Tyr Tyr Cys Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val  
ATC TAT TAC TGT ACG GGT TCT TAC TAT GGT ATG GAC TAC TGG GGT CAA GGA ACC TCG GTC  
Bst EII

Hinge 250  
Thr Val Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys \*\*\* \*\*\*  
ACC GTC TCC AGT GAT AAG ACC CAT ACA TGC CCT CCA TGC TAA TAG GAT CC  
Bam H1  
pGx 5533, Gx 8933

FIG.15B(CONT.)

22 / 39

## CC49/212 SCA<sup>TM</sup> protein genetic dimer

CC49 VL 10 20  
 Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr  
GAC GTC GTG ATG TCA CAG TCT CCA TCC CCT GTG TCA GTT GGC GAG AAG GTT ACT  
 Aat II  
 . 30 40  
 Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala  
 TTG AGC TGC AAG TCC AGT CAG AGC CTT TTA TAT AGT GGT AAT CAA AAG AAC TAC TTG GCC  
 . 50 60  
 Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg  
 TGG TAC CAG CAG AAA CCA GGG CAG TCT CCT AAA CTG CTG ATT TAC TGG GCA TCC GCT AGG  
 . 70 80  
 Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser  
 GAA TCT GGG GTC CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC TCC  
 . 90 100  
 Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr  
 ATC AGC AGT GTG AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT CAG CAG TAT TAT AGC TAT  
 . 110 212 Linker 120  
 Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu Lys Gly Ser Thr Ser Gly Ser Gly  
 CCC CTC ACG TTC GGT GCT GGG ACC AAG CTT GTG CTG AAA GGC TCT ACT TCC GGT AGC GGC  
 Hind III  
 CC49 VH 140  
Lys Ser Ser Glu Gly Lys Gly Gln Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys  
 AAA TCC TCT GAA GGC AAA GGT CAG GTT CAG CTG CAG CAG TCT GAC GCT GAG TTG GTG AAA  
 PvuII PstI  
 . 150 160  
 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala  
 CCT GGG GCT TCA GTG AAG ATT TCC TGC AAG GCT TCT GGC TAC ACC TTC ACT GAC CAT GCA  
 . 170 180  
 Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr Phe Ser Pro  
 ATT CAC TGG GTG AAA CAG AAC CCT GAA CAG GGC CTG GAA TGG ATT GGA TAT TTT TCT CCC

FIG. 16A

23/39

CC49/212 SCAT<sup>TM</sup> protein genetic dimer

190	200
Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp GGA AAT GAT GAT TTT AAA TAC AAT GAG AGG TTC AAG GGC AAG GCC ACA CTG ACT GCA GAC	
210	220
Lys Ser Ser Ser Thr Ala Tyr Val Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val AAA TCC TCC AGC ACT GCC TAC GTG CAG CTC AAC AGC CTG ACA TCT GAG GAT TCT GCA GTG	
230	240
Tyr Phe Cys Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val TAT TTC TGT ACA AGA TCC CTG AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC	
CC49 VL	250
Ser Ser Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly Glu Lys TCC TCA <u>GAC GTC</u> GTG ATG TCA CAG TCT CCA TCC TCC CTA CCT GTG TCA GTT GGC GAG AAG Aat II	
270	280
Val Thr Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr GTT ACT TTG AGC TGC AAG TCC AGT CAG AGC CTT TTA TAT AGT GGT AAT CAA AAG AAC TAC	
290	300
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser TTG GCC TGG TAC CAG CAG AAA CCA GGG CAG TCT CCT AAA CTG CTG ATT TAC TGG GCA TCC	
310	320
Ala Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr GCT AGG GAA TCT GGG GTC CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT	
330	340
Leu Ser Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr CTC TCC ATC AGC AGT GTG AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT CAG CAG TAT TAT	
350	212 Linker
Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu Lys <u>Gly Ser Thr Ser Gly</u> AGC TAT CCC CTC ACG TTC GGT GCT GGG ACC AAG CTT GTG CTG AAA GGC TCT ACT TCC GGT Hind III	
CC49 VH	360
Ser Gly Lys Ser Ser Glu Gly Lys Gly Gln Val Gln Leu Gln Gln Ser Asp Ala Glu Leu AGC GGC AAA TCC TCT GAA GGC AAA GGT CAG GTT <u>CAG CTG CAG</u> CAG TCT GAC GCT GAG TTG PvuII PstI	

FIG.16B

24/39

CC49/212 SCAT<sup>TM</sup> protein genetic dimer

390 400  
Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp  
GTG AAA CCT GGG GCT TCA GTG AAG ATT TCC TGC AAG GCT TCT GGC TAC ACC TTC ACT GAC

410 420  
His Ala Ile His Trp Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr Phe  
CAT GCA ATT CAC TGG GTG AAA CAG AAC CCT GAA CAG GGC CTG GAA TGG ATT GGA TAT TTT

430 440  
Ser Pro Gly Asn Asp Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr  
TCT CCC GGA AAT GAT GAT TTT AAA TAC AAT GAG AGG TTC AAG GGC AAG GCC ACA CTG ACT

450 460  
Ala Asp Lys Ser Ser Ser Thr Ala Tyr Val Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser  
GCA GAC AAA TCC TCC AGC ACT GCC TAC GTG CAG CTC AAC AGC CTG ACA TCT GAG GAT TCT

470 480  
Ala Val Tyr Phe Cys Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val  
GCA GTG TAT TTC TGT ACA AGA TCC CTG AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC

Thr Val Ser \*\*\* \*\*\* Asp  
ACC GTC TCC TAA TAG GAT CC  
Bam H1

FIG.16C

25/39

1 2 3

**200,000 -****97,400 -****68,000 -****43,000 -****29,000 -**

FIG. 17

26/39




FIG. 18

27/39

4-4-20  $V_L$ /217/CC49  $V_H$  gene

4-4-20 $V_L$	10	20	
Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser			
<u>GAC GTC</u> GTT ATG ACT CAG ACA CCA CTA TCA CTT CCT GTT AGT CTA GGT GAT CAA GCC TCC			
Aat II			
	30	40	
Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu Arg Trp			
ATC TCT TGC AGA TCT AGT CAG AGC CTT GTA CAC AGT AAT GGA AAC ACC TAT TTA CGT TGG			
	50	60	
Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Val Leu Ile Tyr Lys Val Ser Asn Arg Phe			
TAC CTG CAG AAG CCA GGC CAG TCT CCA AAG GTC CTG ATC TAC AAA GTT TCC AAC CGA TTT			
	70	80	
Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile			
TCT GGG GTC CCA GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA GAT TTC ACA CTC AAG ATC			
	90	100	
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro			
AGC AGA GTG GAG GCT GAG GAT CTG GGA GTT TAT TTC TGC TCT CAA AGT ACA CAT GTT CCG			
	110	217 Linker	120
Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys <u>Gly Ser Thr Ser Gly Lys Pro Ser</u>			
TGG ACG TTC GGT GGA GGC ACC <u>AAG CTT</u> GAA ATC AAA GGT TCT ACC TCT GGT AAA CCA TCT			
Hind III			
$V_H$	130	140	
<u>Glu Gly Lys Gly</u> Gln Val Gln Leu Gln Gln Ser Asp Ala Glu Leu Val Lys Pro Gly Ala			
<u>GAA GGC AAA GGT</u> <u>CAG GTT CAG</u> CTG CAG CAG TCT GAC GCT GAG TTG GTG AAA CCT GGG GCT			
PvuII PstI			
	150	160	
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His Ala Ile His Trp			
TCA GTG AAG ATT TCC TGC AAG GCT TCT GGC TAC ACC TTC ACT GAC CAT GCA ATT CAC TGG			
	170	180	
Val Lys Gln Asn Pro Glu Gln Gly Leu Glu Trp Ile Gly Tyr Phe Ser Pro Gly Asn Asp			
GTG AAA CAG AAC CCT GAA CAG GGC CTG GAA TGG ATT GGA TAT TTT TCT CCC GGA AAT GAT			

FIG. 19A

28/39

4-4-20 V<sub>L</sub>/217/CC49 V<sub>H</sub> gene

190 200  
Asp Phe Lys Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser  
GAT TTT AAA TAC AAT GAG AGG TTC AAG GGC AAG GCC ACA CTG ACT GCA GAC AAA TCC TCC  
210 220  
Ser Thr Ala Tyr Val Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys  
AGC ACT GCC TAC GTG CAG CTC AAC AGC CTG ACA TCT GAG GAT TCT GCA GTG TAT TTC TGT  
230 240  
Thr Arg Ser Leu Asn Met Ala Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser \*\*\* \*\*\*  
ACA AGA TCC CTG AAT ATG GCC TAC TGG GGT CAA GGA ACC TCA GTC ACC GTC TCC TAA TAG

Asp  
GAT CC  
Bam H1

FIG.19A(CONT.)

29/39

CC49  $\text{V}_L$  / 217/4-4-20  $\text{V}_H$  gene

CC49  $\text{V}_L$  10 20  
 Asp Val Val Met Ser Gln Ser Pro Ser Ser Leu Pro Val Ser Val Gly Glu Lys Val Thr  
GAC GTC GTG ATG TCA CAG TCT CCA TCC CTA CCT GTG TCA GTT GGC GAG AAG GTT ACT  
Aat II

30 40  
 Leu Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala  
 TTG AGC TGC AAG TCC AGT CAG AGC CTT TTA TAT AGT GGT AAT CAA AAG AAC TAC TTG GCC

50 60  
 Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg  
 TGG TAC CAG CAG AAA CCA GGG CAG TCT CCT AAA CTG CTG ATT TAC TGG GCA TCC GCT AGG

70 80  
 Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Thr Asp Phe Thr Leu Ser  
 GAA TCT GGG GTC CCT GAT CGC TTC ACA GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC TCC

90 100  
 Ile Ser Ser Val Lys Thr Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr  
 ATC AGC AGT GTG AAG ACT GAA GAC CTG GCA GTT TAT TAC TGT CAG CAG TAT TAT AGC TAT

110 217 Linker 120  
 Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Val Leu Lys Gly Ser Thr Ser Gly Lys Pro  
CCC CTC ACG TTC GGT GCT GGG ACC AAG CTT GTG CTG AAA GGC TCT ACT TCC GGT AAA CCA  
Hind III

4-4-20  $\text{V}_H$  130 140  
Ser Glu Gly Lys Gly Glu Val Lys Leu Asp Glu Thr Gly Gly Leu Val Gln Pro Gly  
TCT GAA GGT AAA GGT GAA GTT AAA CTG GAT GAG ACT GGA GGA GGC TTG GTG CAA CCT GGG

150 160  
 Arg Pro Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met Asn  
 AGG CCC ATG AAA CTC TCC TGT GTT GCC TCT GGA TTC ACT TTT AGT GAC TAC TGG ATG AAC

170 180  
 Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Gln Ile Arg Asn Lys Pro  
 TGG GTC CGC CAG TCT CCA GAG AAA GGA CTG GAG TGG GTA GCA CAA ATT AGA AAC AAA CCT

FIG.19B

CC49  $\nu_L$  /217/4-4-20  $\nu_H$  gene 190 200  
Tyr Asn Tyr Glu Thr Tyr Tyr Ser Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp  
TAT AAT TAT GAA ACA TAT TAT TCA GAT TCT GTG AAA GGC AGA TTC ACC ATC TCA AGA GAT

210 220  
Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Asn Leu Arg Val Glu Asp Met Gly Ile  
GAT TCC AAA AGT AGT GTC TAC CTG CAA ATG AAC AAC TTA AGA GTT GAA GAC ATG GGT ATC

230 240  
Tyr Tyr Cys Thr Gly Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr  
TAT TAC TGT ACG GGT TCT TAC TAT GGT ATG GAC TAC TGG GGT CAA GGA ACC TCA GTC ACC

Val Ser \*\*\* \*\*\* Gly Ser  
GTC TCC TAA TAA GGA TCC  
Bam H1

FIG.19B(CONT.)

31/39


PROCESSING FILE: PolyCatA/Proc.CC-49Prep

METHOD: PREP POLY CAT A#2

INJECT VOL: 44

SAMPLING INT: 0.3 SECONDS

CHROMATOGRAM:



ANALYSIS: CHANNEL A

PEAK NO.	TIME	TYPE	HEIGHT(μV)	AREA(μV-SEC)	AREA%
1	17.090	N1	1651	348239	0.778
2	18.940	N2	8014	669441	1.496
3	21.775	N3	104401	8617252	19.263
4	30.100	N4	74925	9753616	21.804
5	33.455	N5	106864	15749605	35.208
6	38.940	N6	17296	2833701	6.334
7	42.010	N7	12645	1637917	3.661
8	44.640	N8	9287	1968584	4.400
9	57.055	N9	13767	2012338	4.498
10	57.610	N10	9323	210914	0.471
11	58.240	X11	6824	930855	2.080
TOTAL AREA				44732462	99.993

FIG.20

32/39




FIG. 21

33/39


PROCESSING FILE: PolyCatA/Proc.CC-49Prep

METHOD: CC-49 QC SIZE-EXCLUSION

INJECT VOL: .05

SAMPLING INT: 0.1 SECONDS

CHROMATOGRAM:



ANALYSIS: CHANNEL A

PEAK NO.	TIME	TYPE	HEIGHT(μV)	AREA(μV-SEC)	AREA%
1	19.370	N1	797	41706	5.694
2	20.525	N2	11789	657280	89.737
3	22.851	N3	1227	33466	4.569
				732452	100.000

TOTAL AREA

FIG.22A

34/39


PROCESSING FILE: PolyCatA/Proc.CC-49Prep

METHOD: CC-49 QC SIZE-EXCLUSION

INJECT VOL: .05

SAMPLING INT: 0.1 SECONDS

CHROMATOGRAM:



ANALYSIS: CHANNEL A

PEAK NO.	TIME	TYPE	HEIGHT(μV)	AREA(μV-SEC)	AREA%
1	19.133	N1	14211	749671	88.214
2	20.538	N2	1863	100154	11.785
				849825	99.999


TOTAL AREA

FIG.22B

35/39

PROCESSING FILE: PolyCatA/Proc.CC-49Prep  
METHOD: CC-49 QC SIZE-EXCLUSION  
INJECT VOL: .05  
SAMPLING INT: 0.1 SECONDS

CHROMATOGRAM:



ANALYSIS: CHANNEL A

PEAK NO.	TIME	TYPE	HEIGHT(μV)	AREA(μV-SEC)	AREA%
1	19.163	N1	17550	876502	83.039
2	20.435	N2	2981	179029	16.961
TOTAL AREA				1055531	100.000

FIG.22C

36/39




FIG. 23

37/39




FIG. 24

38/39




FIG. 25

39/39




FIG. 26

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/09965

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C07K 15/28, 3/20; C07H 21/04; C12P 21/08; C12N 15/00, 15/03;

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/387.3, 413; 435/7.92, 7.93, 7.94, 69.6, 69.7, 70.21, 172.2, 172.3, 240.27, 252.3, 320.1; 424/1.1, 85.8; 536/23.4, 23.53

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG (FILES 5, 73, 155, 351); U.S. AUTOMATED PATENT SYSTEM (FILE USPAT, 1971-PRESENT).


## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 88/09344 (HUSTON et al.) 01 DECEMBER 1988, see entire document.	<u>1-33,38-39,44-63</u>
Y		34-37,40-43
X	US, A, 4,946,778 (LADNER et al.) 07 AUGUST 1990, see entire document.	<u>32-33,38-39</u>
Y		1-31,34-37,40-63
Y	CANCER RESEARCH, Vol. 48, issued 15 AUGUST 1988, Muraro et al., "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen," pages 4588-4596, see entire document.	34-37,40-43
Y	SCIENCE, Vol. 242, issued 21 OCTOBER 1988, Bird et al., "Single-Chain Antigen-Binding Proteins," pages 423-426. See entire document.	32-42
Y	JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 265, No. 30, issued 25 OCTOBER 1990, Bedzyk et al., "Immunological and Structural Characterization of a High Affinity Anti-fluorescein Single-chain Antibody," pages 18615-18620. See entire document.	32-42

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
--------------------------	--	--------------------------	--------------------------

• Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
• A document defining the general state of the art which is not considered to be part of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
• E earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
• L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		
• O document referring to an oral disclosure, use, exhibition or other means	&	document member of the same patent family
• P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
23 FEBRUARY 1993	05 MAR 1993

Name and mailing address of the ISA/Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer ROBERT D. BUDENS Telephone No. (703) 308-0196
Facsimile No. NOT APPLICABLE	

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

530/387.3, 413; 435/7.92, 7.93, 7.94, 69.6, 69.7, 172.3, 252.3, 320.1; 424/1.1, 85.8; 536/23.53

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

- I. Claims 1-14, 19-29, 31, 44-46, 51-58, a first product, method of making and method of using, drawn to multivalent antigen-binding proteins, compositions, methods of making multivalent proteins and method of using multivalent proteins to detect antigens, classified in Class 530, subclass 387.3 and Class 435, subclasses 7.1, 69.7, 172.3, 320.1, 252.3.
- II. Claims 15-18, a second product, drawn to compositions containing multivalent proteins and single chain proteins, classified in Class 530, subclass 387.3.
- III. Claim 30, a second method of use, directed to a method of imaging, classified in Class 424, subclass 85.8.
- IV. Claims 32-37, a third product, drawn to single chain proteins classified in Class 530, subclass 387.3.
- V. Claims 38-43 and 47-50, a fourth product, drawn to genetic sequences, vectors and hosts, classified in Class 536, subclass 23.53, Class 435, subclasses 320.1 and 252.3.
- VI. Claims 59-61, a third method of use, drawn to immunoassay methods, classified in Class 435, subclasses 7.92, 7.93 and 7.94.
- VII. Claim 62, a fourth method of use, drawn to a method of immunotherapy using multivalent proteins, classified in Class 424, subclass 85.8.
- VIII. Claim 63, a fifth method of use, drawn to a method of immunoaffinity purification using multivalent proteins, classified in Class 530, subclass 413.

The inventions of Groups I-II and IV-V are directed to multiple products which differ in their physical properties such as primary sequence, molecular weights and chemical composition and are not so linked as to have a common special technical feature.

Further, the methods of Groups I, III and VI-VIII differ in their utilities, reagents and method steps and are not so linked as to have a common special technical feature.